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ABSTRACT 
 
Compensatory liver regeneration is triggered by chronic liver injury or surgery and is crucial to 
maintain tissue homeostasis. The underlying mechanisms which include a whole battery of 
complex signaling events have been thoroughly studied for decades. The majority of 
hepatocellular carcinomas develop in a highly proliferative environment caused by underlying 
chronic liver disease in which lost liver tissue must be restored to meet the needs of the 
organism. The chronic inflammatory condition with chronic liver repair enhances the presence 
of free radicals leading to an increased risk of cell alterations.  
This thesis includes four papers; the first three of which comprise studies regarding the 
importance of the regulation and endurance of cell proliferation, and also the sensitivity of the 
proliferating cells to compounds used in cancer prevention and treatment. In these studies we 
used a 2/3 partial hepatectomy (PH) rat model and also a chemically induced rat liver cancer 
model (The Solt and Farber Resistant hepatocyte model). The fourth paper is a human study in 
which we quantified immunohistochemical stainings for 6 different redox proteins in livers 
from patients resected for hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) 
liver metastases. 
The specific aims were: (I) to characterize gene expression of the different pathways involved 
in hepcidin regulation after PH, until liver regeneration is complete; (II) to study the effects of 
sodium selenite on regenerative versus neoplastic liver cell proliferation in rat, and to 
investigate if TrxR1 is a constitutive tumour marker or an unspecific marker for cell growth in 
rat liver; (III) to study the effect of the anticancer agent sorafenib, a multikinase inhibitor, on 
normal liver regeneration after PH in rat; and  (IV) to evaluate if redox protein (thioredoxins 
and glutaredoxins) expressions correlate to clinical features in human hepatocellular 
carcinoma and if they can be used as prognostic markers after liver surgery.  
Our results showed that high serum levels of IL6 induced the levels of STAT3 and the 
expression of hepcidin mRNA during the acute phase after PH. The gene expressions of the 
iron sensing proteins HFE, hemojuvelin (HJV) and transferrin receptor 2 (TfR2) were decreased 
during the whole regeneration, gradually decreasing hepcidin gene expression and thereby 
mobilizing iron to the growing liver. The expression of genes involved in iron uptake; 
transferrin receptor 1 (TfR1) and divalent metal transporter 1 (DMT1) were increased thereby 
facilitating iron uptake (paper I).  
After administration of sodium selenite in a tumour preventive, supranutritional dose followed 
by PH no effect on body weights or gain of liver mass was seen. In the hepatocarcinogenesis 
model the tumour volume was significantly decreased in animals supplied with selenium 
during the progression phase compared tumours in rats not treated with selenium. The 
expression of TrxR1 was exclusively seen in the neoplastic liver lesions but not in the 
remodelling preneoplastic lesions (paper II). 
Treatment with sorafenib transiently suppressed liver regeneration and the gain of relative 
liver mass, but was followed by a delayed compensatory increase of liver cell proliferation one 
week after resection with the result that after 14 days the treated animals reached the same 
relative liver weights as the controls did in five days (paper III). 
In the human study we saw an up-regulation of Trx1, Trx2 and Grx5 in HCC compared to its 
respective surrounding non-tumorous tissue. The same was observed in the CRC metastases 
where also the staining of Grx1 and Grx3 was significantly higher compared to non-tumorous 
  
tissue. Trx1 expression correlated well to cell proliferation but not to tumour differentiation, 
micro-vascular invasion or tumour recurrence. A relative down regulation of Trx1 was seen in 
tumours compared to the surrounding liver in males, smokers and in patients with high alcohol 
consumption.  
 
We concluded that the peak of hepcidin expression during the acute phase was eventually 
overruled by the downregulation of the iron sensing pathway in order to promote iron 
mobilization to the regenerating liver. We also concluded that selenium in a supranutritional 
dose impaired tumour growth without impairing the normal liver cell proliferation, and that 
the selenoprotein TrxR1 is a constituent of the neoplastic phenotype. Sorafenib prolonged 
liver regeneration in proportion to the length of treatment but the liver adapted to the early 
inhibitory effects of the drug. Thioredoxins and glutaredoxins were ubiquitously expressed in 
livers exposed to oxidative stress and various malignancies and can therefore not be used as 
diagnostic markers for HCC. Smoking and high alcohol consumption increased the Trx1 
expression in tissue surrounding the HCCs, whereas expression of Trx1 in the HCCs correlated 
to cell proliferation. Redox protein expression in HCCs cannot be used as predictive markers 
for tumour recurrence after liver resection. 
  
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Levern är kroppens största körtel och kroppens näst största organ efter huden. Den är ett 
mångfacetterat organ med uppgifter som att producera essentiella proteiner, till exempel 
koagulationsfaktorer, lagra energi i form av glykogen, producera och utsöndra vissa hormoner, 
producera och transportera galla till tarmen för fettnedbrytning, reglera upptag av järn samt 
bryta ner toxiska kemiska föreningar. Utöver detta har levern också en viktig roll i 
immunförsvaret för att eliminera främmande partiklar såsom virus och bakterier. 
 
Levern har en stor förmåga till anpassning efter behovet av funktionell levermassa men också 
en betydande reservkapacitet. Levern har förmågan att återuppbyggas efter skador, genom att 
levercellerna delar sig vilket kallas leverregeneration. Sådana skador kan uppstå på grund av 
en kronisk leverinflammation eller efter ett kirurgiskt ingrepp där en bit av levern opereras 
bort. Vid en kronisk leverskada orsakad exempelvis av hepatit B/C eller alkohol så ökar risken 
för ackumulerade mutationer, som på sikt kan leda till tumörer. Ett helt maskineri av komplexa 
signalvägar ligger bakom leverregeneration och om man i detalj kan kartlägga dessa skulle nya 
strategier för behandling av levercancer kunna utvecklas. 
Vid primär levercancer kan symptomen vara vaga och uppstå i ett sent skede. Om cancern 
upptäcks i ett tidigt stadium kan patienten behandlas kirurgiskt om den upptäcks i ett 
intermediärt stadium kan cellgifter sprutas in i leverartären till tumören, men om den hittas i 
ett avancerat stadium kan man bara ge en ”bromsmedicin”, sorafenib, som hämmar tumörens 
tillväxt men inte ger bot. 
I den här studien har vi använt en djurmodell på råtta för att kunna studera leverregeneration 
och hur den påverkas av olika behandlingar. Sjuttio procent av djurets lever tas bort i ett 
kirurgiskt ingrepp som kallas 2/3 partiell hepatektomi, (PH). Den återstående delen av levern 
kommer omedelbart att starta en kompensatorisk regenerationsprocess och på råtta ser man 
redan efter 5-7 dagar att vävnadsförlusten är ersatt och levern har nått sin ursprungliga 
funktionella massa för att möta organismens behov. 
 
Det finns sjukdomar som leder till för högt järnupptag vilket på sikt är levertoxiskt och kan leda 
till levercancer. Vi har studerat hepcidin som är ett protein som styr järnupptaget i levern 
genom att blockera upptaget från tarmen. Hepcidinet självt produceras av levern och regleras 
av flera molekyler som känner av järnhalten i kroppen. Vid inflammation uppregleras hepcidin 
vilket ger en minskning av järnhalten i plasma. Detta ses som ett försvar mot mikroorganismer 
som har behov av järn för att kunna föröka sig. Efter partiell hepatektomi följer en akutfas-
reaktion som bland annat leder till en ökad produktion av hepcidin. Den akuta fasen är över 
efter ett dygn och övergår i en regenerativ fas. Det var tidigare inte känt vad som sker med 
uttrycket av hepcidin och därmed regleringen av järnupptaget under själva regenerationsfasen 
av leverns återuppbyggnad, vilket föranledde oss att genomföra den här studien. Vi använde 
oss av PH-djurmodellen och analyserade uttrycket av hepcidinreglerande gener och proteiner 
och fann att hepcidin nedreglerades efter den akuta fasen för att underlätta upptaget av järn 
som är en viktig komponent under celldelning och celltillväxt. 
Selen är ett annat grundämne som är ett viktigt spårämne i kroppen, och som är inblandat i 
många viktiga cellulära processer, bland annat celltillväxt och cellulär utmognad 
(differentiering). Det finns studier som har visat att selen har en hämmande effekt på olika 
  
typer av tumörer. Vi studerade selenets inverkan på levercancer i råtta och fann att selen, i en 
dos som är högre än normalt dagssintag men som inte är toxisk, hämmade levertumörernas 
tillväxt utan att påverka den normala leverns tillväxt. Vi undersökte även förekomsten av ett 
selenoprotein, thioredoxin reduktas 1 (TrxR1) som är involverat i cellens försvar mot oxidativ 
stress, i tumörerna och fann att detta protein överuttrycktes i levertumörer men inte i de 
cellförändringar utgör ett förstadium till tumör och som var på väg att återbildas. Vi drog 
slutsatsen att TrxR1 är en del av tumörcellens karakteristika (vilket brukar kallas den 
”neoplastiska fenotypen”) och skulle kunna användas som en vävnadsmarkör för cancer. 
 
Vi studerade även sorafenib som är en relativt ny medicin som ges till patienter med 
avancerad inoperabel levercancer. Sorafenib verkar genom att hämma vissa cellulära 
signalvägar som är inblandade i celldelningen. Frågan har väckts om sorafenib skulle kunna 
användas i samband med kirurgi för att minska risken för återfall av sjukdomen. Ett problem är 
dock att sorafenib också kan hämma normala leverceller som ska dela sig för att återställa 
förlorad vävnad efter operation.  
Av den anledningen valde vi att studera effekten av sorafenib på normala tillväxande 
leverceller hos råtta efter PH. Djuren fick sorafenib dagligen under en vecka innan PH och 
avlivades vid olika tidpunkter därefter. Vi studerade leverns tillväxt upp till 14 dagar efter 
operationen och fann att sorafenib hämmade tillväxten i proportion till längden på 
behandlingen efter PH samt att levern anpassade sig till drogen genom att öka sin celldelning i 
ett senare skede efter PH. Detta för att kompensera för den tidiga hämmande effekten. Efter 
14 dagar var de sorafenib-behandlade djurens levrar lika stora som innan, medan detta tog 5 
dagar hos de djur som inte fått sorafenib.  
 
Uttrycket av vissa redoxproteiner har rapporterats vara ökat i bland annat tjocktarms- och 
gallblåsecancer, och dessutom korrelerats till en sämre prognos efter kirurgi. För att studera 
om detta även gäller levercancer så analyserade vi uttrycket av sex olika redoxproteiner i 
kirurgiskt avlägsnade levertumörer hos patienter med primär levercancer. Som 
jämförelsematerial använde vi dels omgivande levervävnad runt tumörerna och dels 
levermetastaser från tjocktarmscancer samt den tumörfria levern som omgav metastaserna. 
Vi fann att flera av dessa proteiner var signifikant uppreglerade i tumörerna jämfört med den 
omgivande vävnaden men att uppregleringen var svagare i primär levercancer jämfört med 
tjocktarmscancermetastaserna.  
Vi fann även ett starkare uttryck av proteinerna i den omgivande vävnaden i levrarna med 
primär levercancer jämfört med uttrycket i den vävnad som omgav tjocktarmsmetastaserna. 
Detta tror vi speglar en högre grad av oxidativ stress (bildning av fria radikaler) hos 
levercancerpatienterna beroende på deras underliggande kroniska leversjukdom jämfört med 
levervävnaden hos patienterna med metastaser, där levervävnaden i grunden är frisk. Vi såg 
inget samband mellan uttrycket av redoxproteiner och risken att återfå sin levercancer efter 
operationen. 
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PREFACE 
 
The liver is a fascinating and diverse organ with many challenging tasks. Positioned under the 
ribs on the right side of the abdomen, and with a direct contact with the intestine via the 
portal vein it is the first organ receiving and taking care of anything that is ingested. The liver is 
not only the biggest organ on the inside of our body with a weight of 1.2 -1.5 kilograms in 
adults, but also our largest gland. 
It has a major role in the body’s metabolism and produces important plasma proteins and 
lipids; it synthesizes and excretes bile, and functions moreover as a huge reservoir of several 
important biomolecules. 
With its double blood supply the liver is fraught with venous and nutrient rich blood from the 
intestines and spleen brought via the portal vein whereas the hepatic artery supplies the liver 
with oxygenated blood. These vessels lie parallel and enter the liver through the porta hepatis 
where they divide into branches to the right and the left lobes. The left and the right hepatic 
bile ducts form the common hepatic duct which exits the liver where the vessels enter. The 
hepatic nerve plexus follows the hepatic artery and bile ducts into the hepatic parenchyma.  
The gallbladder is a reservoir that collects the bile produced by the liver. The bile is emptied in 
the intestines to help breaking down lipids which are taken up by the epithelial cells that lines 
the intestinal mucosa for subsequently transportation via the portal vein to the liver for 
further processes. 
The liver consists of two anatomical lobes; the right lobe is bigger and constitutes 60-65% of 
the whole liver. The lobes are separated by ligamentum falciforme hepatis. Each lobe is 
organized in functional segments where they have independent vascular and biliary stalks and 
venous drainage. In total the liver has 8 segments designated I-VIII. 
One of the most unique features of this organ is its capability to regenerate; something which 
is a very important evolutionary adaptation for a life on our planet, with its variable 
environment that sometimes can be very hostile.  
Already the ancient Greeks had some idea of liver regeneration, in Greek mythologies there is 
a story about Prometheus – an immortal titan- that was stealing the fire from the Gods in 
Olympia to give to the people. For this he was punished by Zeus for all eternity by being 
fettered to a rock and getting his liver eaten every day by an eagle. Each night a new liver grew 
back so that the eagle could feast on a fresh liver the next day and this endless torture went 
on until he was eventually released and the eagle was shot. 
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1 INTRODUCTION 
The liver is a very plastic gland that in a changing environment is constantly adapting its 
functions to the needs of the body. It has an impressive capacity and flexibility that we hardly 
ever think of or has to consider in daily life. It is however also a target for environmental 
toxicity and disease. With efficient repair processes, including intracellular restoration of 
organelles as well as regeneration of new hepatocytes, the liver can compensate for a 
significant loss of liver cells and liver cell function. Acute toxicity is therefore usually not life 
threatening unless the entire liver is severely compromised. Chronic toxicity and chronic 
necroinflammatory diseases, involving cell degeneration and cell death induce chronic repair 
processes and a need for chronic regeneration. Increased compensatory cell proliferation in a 
toxic environment and in an environment with increased oxidative stress causes with time 
chronic liver damage, liver fibrosis and increases the risk of liver cancer. 
 
In this thesis we have focused on the compensatory hepatocyte cell proliferation, involved in 
liver cancer development. We have investigated different aspects of importance for the 
regulation and endurance of cell proliferation and also the sensitivity of the proliferating cells 
to compounds used in cancer prevention and treatment. An important function of the liver cell 
is to be able to handle reactive compounds and oxidative stress. We have therefore also 
investigated the expression of redox proteins in liver cancer and in the surrounding non 
neoplastic liver in which the tumour has developed and that is of importance also for the 
growth of the cancer cells and cancer progression. The patient is dependent for its survival on 
the status of the surrounding liver tissue and a severely compromised surrounding liver tissue 
will also limit the options available for treatment. 
 
The thesis covers the homeostasis of iron in a situation of sustainable restoration after 
removal of 2/3 of the liver tissue. We also investigate the effect on selenium on the growth of 
the normal hepatocyte and compare that with data on the selenium effect on liver cancer and 
liver cancer development. This is of interest in a situation where selenium is used to prevent 
liver cancer in a patient with chronic liver disease. Sorafenib is today the only compound used 
for treatment of advanced liver cancer with any effect on the survival. It has been suggested 
that this compound should be used in patients that has gone through a liver resection to 
remove the liver cancer. We have looked at the effect of sorafenib on the non-neoplastic 
growing hepatocyte. Finally we have investigated thioredoxins and glutaredoxins, proteins 
involved in cellular oxidative defense that could be involved in the resistant phenotype of liver 
cancer and have been suggested as potential markers for liver cancer. 
 
1.1 THE CELLS OF THE LIVER  
1.1.1 Parenchymal cells 
The hepatocytes build up the liver parenchyma and constitute the functional units of the liver, 
and are therefore named “liver parenchymal cells”.  
The hepatocytes are relatively large in size compared to other cells in the liver. About 80% of 
the liver volume is composed of hepatocytes, but in numbers, hepatocytes constitute only 
around 60% of the total number of cells. The shape of the nucleus of the hepatocyte is 
spherical and contains one or more nucleoli. About 25% of the hepatocytes are binuclear in an 
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adult healthy liver. The functions of the hepatocytes display a broad variety and they are one 
of the most complex and metabolically diverse cells in the body. They synthesize plasma 
proteins, glucose, lipoproteins, cholesterol, phospholipids and fatty acids. They take up, store 
and control the release of nutrients into the circulation. Through the bile secretion they help 
to digest and absorb dietary fats and furthermore they degrade, detoxify and excrete 
exogenous and endogenous compounds.  The work load of the liver is under strict control and 
adapts to the need of the organism in a fine-tuned way. The mechanisms or adaptation 
includes hyperplasia and involution as well as hypertrophy and atrophy. 
The hepatocytes are very rich in organelles such as endoplasmic reticulum (ER), mitochondria, 
lysosomes and peroxisomes. The ER is highly active and has many different functions in 
hepatocytes such as synthesis of structural membrane proteins, proteins and glycoproteins for 
secretion into the blood, metabolism of fatty acids, triglycerides and phospholipids, 
metabolism and production of cholesterol, metabolism of xenobiotics, ascorbic acid synthesis 
and degradation of heme. Heme is an important component of cytochromes and is 
synthesized by the granulated rough ER (RER) with ribosomes attached in polysome groups. 
The brown color of the liver is due to the high content of heme. Bilirubin will be conjugated by 
the hepatocytes to glucuronic acid and subsequently secreted into the bile. 
There is more of rough ER (RER) in hepatocytes compared to smooth ER (SER) which are not 
coated with ribosomes. While RER is responsible for protein synthesis, endogenous as well as 
proteins for export, SER contain enzymes for drug metabolism, biosynthesis of cholesterol and 
conversion of cholesterol to bile acids. SER is also involved in posttranslational modifications of 
proteins, such as glycosylation and formation of lipoproteins. 
The functional heterogeneity is facilitated by the morphology of the hepatocytes i.e. the 
exocrine function with secretion of bile to the canaliculus, as well as the endocrine function 
that involves the synthesis of proteins and other compounds that enter the sinusoids.  
 
1.1.2 Non-parenchymal cells 
The non-parenchymal cells (Kupffer cells, stellate cells, endothelial cells, bile duct cells, 
fibroblasts and lymphocytes) constitute approximately 40% of cells in the liver. Kupffer cells 
are specialized macrophage-like cells that are important in the phagocytosis and break-down 
of cell debris. Like other reticuloendothelial macrophages they lyse red blood cells and heme 
and the globin chains are catabolized into polypeptides for re-use and heme is broken down 
into biliverdin and iron. Biliverdin will be further converted to bilirubin and iron will be bound 
to transferrin for transport or to ferritin for storage (see the iron section on page 17). Like 
other immune cells Kupffer cells play a role in the defense against infections and they respond 
highly to acute-phase proteins. They also play important roles in signaling during liver 
regeneration and inflammation and release a variety of immunoregulatory compounds like IL-
1, IL6, TGFβ and TNFα. They also express MHC class II molecules and they process and present 
antigens to lymphocytes. 
The stellate cells are pericytes which also are called Ito cells or fat-storing cells. These cells are 
found in the space of Disse; they store vitamin A under normal conditions and form 
extracellular matrix like laminin, collagen type IV and fibronectin. They also regulate the tonus 
in the sinusoids and thereby regulate the blood flow. In response to liver damage they are 
activated, transforms into myofibroblasts and form scar tissue by changing their components 
of secreted matrix proteins to collagen type I and III and simultaneously break down the 
normal matrix proteins. By these mechanisms stellate cells are involved in the formation of 
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fibrosis and eventually cirrhosis in chronic liver disease. The sinusoidal endothelial cells are the 
cells lining the sinusoids in the liver, and in contrast to endothelial cells in capillaries in other 
tissues they lack a basement membrane and are fenestrated to facilitate passage of molecules 
[1]. In cirrhosis, the fenestrations are lost, and fibrotic tissue in the space of Disse reduces the 
exchange of metabolites between the blood and hepatocytes (Figure 1). 
 
Figure 1.  A simplified picture of the microscopic architecture of the liver sinusoid in a normal 
condition and in fibrosis. The upper panel demonstrates normal hepatocytes with microvilli, 
gap junctions and tight junctions. The stellate cells and the Kupffer cells are inactive, the 
extracellular matrix is normal, and there are fenestrations between and through the 
endothelial cells. The lower panel demonstrates a fibrotic liver; the microvilli of the hepatocytes 
are lost, the activated stellate cells have been transformed to myofibroblasts and produces 
collagen. The Kupffer cells will also migrate to the damaged area and release cytokines that 
will further enhance the inflammation.  
 
  
1.1.3 Hepatocellular metabolism 
The liver is the major site for protein and amino acid metabolism in the body and the uptake of 
ingested proteins starts by degradation in the gastro-intestinal tract. Proteins are cleaved to 
shorter chains by proteolytic enzymes and will by efficient hydrolysis yield free amino acids. 
The amino acids are absorbed by the gut mucosa and transported to the liver via the portal 
vein. Humans have the capacity to synthesize 10 of the 20 amino acids needed to build up 
proteins. Those 10 amino acids that we cannot make ourselves are thus essential and have to 
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be ingested via the food. About 400 g of protein is turned over daily in a normal-sized man 
where 75% is degraded and recycled through constituent amino acids [2]. The remaining 25% 
is degraded via oxidation or converted into glucose.  
 For the uptake of amino acids into the hepatocyte there are several sodium-dependent 
membrane transport systems on the sinusoidal side of the cell [3, 4].  The liver can also take up 
large proteins from plasma with a very efficient receptor-mediated endocytosis; for example it 
is estimated that one single hepatocyte can engulf 5 million molecules of asialoglycoprotein 
per hour [5, 6]. The endocytosed proteins are directed to the lysosomal compartment for 
further degradation. Examples of proteins that are taken up either via specific receptors or by 
fluid-phase endocytosis are: IgA, EGF, TGFβ, low-density lipoproteins (LDL) asialoglycoproteins, 
hemopexin, albumin and immunoglobulins. 
The liver synthesizes the essential amino acids needed and it produces and secretes more than 
90% of circulating plasma proteins, the most prominent of which is albumin. The hepatocytes 
also produce enzymes, receptors, membrane channels and transport proteins to be used 
within the cell. Other plasma proteins that are secreted by hepatocytes are blood clotting 
factors, ceruloplasmin and α-1-antitrypsin to mention some. 
Ingested fatty acids, mostly triglycerides, are broken down to free fatty acids and 
monoglycerides by pancreatic lipase to allow absorption by the intestine. Once inside the 
body they will be reformed into triglycerides and package with apoproteins and cholesterol 
into blood-soluble complexes called chylomicrons. The chylomicrons move across the blood 
vessel membrane and into the bloodstream. These complexes will bind to the membranes of 
hepatocytes, adipocytes and muscle fibers and will within the cells be either oxidized 
forming CO2  and ATP or stored as fat droplets in adipose tissue. Free fatty acids (FFAs) are 
transported to the muscles via serum albumin as an energy source. Also, free fatty acids are 
transported from splanchnic adipose tissue via the portal blood into the liver. Once in the 
liver, FFAs are either oxidized by mitochondria to yield energy or together with glycerol form 
triglycerides as part of very low density lipoproteins (VLDL) synthesis. Excess lipids form 
triglyceride-containing lipid droplets in the cytoplasm of the hepatocytes, a condition named 
fatty liver if the fat content exceeds 5 % of the liver volume. 
 
 
 
1.2 LIVER REGENERATION 
Liver regeneration is a process where lost or damaged liver tissue is replaced to restore the 
functional liver mass. Since the liver is the major organ in the body with detoxifying features, 
the regenerative capability is most likely a result of an evolutionary adaptation to a toxic 
environment on earth.  Liver regeneration occurs as a response to cell damage due to toxic 
injury, necroinflammation or after cell loss (e.g. resection) and the first cells to respond are the 
hepatocytes. 
What triggers regeneration and what are the underlying mechanisms? Hepatocyte cell 
proliferation may be induced by chronic repair in an inflammatory environment, or when the 
liver is exposed to toxins (such as drugs or alcohol). The liver can increase its capacity in 
detoxification by increasing its functional mass via cell renewal –hyperplasia - or by an 
increased size of existing cells –hypertrophy. Hypertrophy may occur transiently after 
resection or after major cell death as a functional compensation before the existing 
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hepatocytes or progenitor cells have been able to proliferate [7].  Hyperplasia on the other 
hand, is the fundamental feature during liver regeneration, and an effect of enhanced cell 
proliferation. The changes in the tissue homeostasis leading to liver regeneration are of crucial 
significance for the organism. However, in all tissues with a high cell proliferation there is an 
increased risk for genetic changes and mutations to occur. Also, the liver is exposed to 
additional oxidative stress in a toxic environment, increasing the risk of cellular damage. 
Agents that may cause liver damage and trigger increased cell proliferation are chronic 
exposure to alcohol, hepatitis virus, iron overload and aflatoxin. Combinations of some of 
these agents can further aggravate the cell damage, such as hepatitis C plus alcohol [8] or 
hepatitis B plus aflatoxin.  
Another major event inducing liver regeneration is surgery, in particular liver resection. Higgins 
and Anderson described the regeneration after partial hepatectomy (PH) already in 1931[9]. In 
the rodent PH-model two-thirds of the liver is surgically removed and the remnant liver 
enlarges until the initial mass is reached [10]. The liver mass is reconstituted in approximately 
5-7 days in rats, and a peak of regenerative activity is seen during the first 3 days after which 
most hepatocytes become quiescent again [11].  Twelve hours after hepatectomy the majority 
of the hepatocytes enters the S-phase and reaches a peak at 24 hours. A complete restoration 
of liver mass requires 1,6 cycles of DNA in all cells, including non-parenchymal cells in which 
DNA synthesis occurs later compared to that seen in hepatocytes [12].  
Basically the same mechanisms of regeneration take place during recovery in a liver exposed 
to toxic cell damage or hepatitis, and after experimentally triggered regeneration following PH, 
except for one major difference. In the rodent PH model, the two biggest lobes are removed 
by ligation of separate liver lobes, leaving the three small remnant lobes to regenerate without 
any damaged tissue and thus no necrosis or apoptosis. In a human liver under toxic stress 
there will be both necrosis and apoptosis and subsequently regeneration to compensate for 
that loss. A new term has appeared to describe the phenomenon of liver regeneration in liver 
tissue homeostasis: “hepatostat”, meaning to explain the vital functions of the liver in relation 
to the needs of the body [13]. 
The expression “liver regeneration” is somewhat misleading since the liver mass and 
functional capacity but not shape is restored. A more correct term would be compensatory 
hyperplasia, since the tissue is replaced by the vast cell proliferation of the remnant lobes in 
which virtually all of the cells will replicate. The regeneration stops when the organism´s 
demands are fulfilled.  
Liver regeneration can be described as different processes which do not exclude one another. 
They may occur in different proportions depending on the extent of the loss of tissue and to 
what extent liver proliferation is impaired.  
The different models described include 1) replacement of tissue loss where each cell type 
replicates to replace its own cellular compartment, 2) replacement of liver tissue by activation 
of transdifferentiation pathways originating from facultative stem cells, 3) an increase in liver 
size known as augmentative hepatomegaly, where an increase in size above baseline is seen 
[15].  
Liver regeneration is complex and is orchestrated by several different pathways involving both 
intrinsic and extrinsic signals, growth factors and cytokines. 
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1.2.1 Initiation of cell proliferation 
Studies of signaling events after PH have been going on for more than two decades and 
experiments intended to completely eliminate single pathways have not revealed any explicit 
pathway to be totally vital for regeneration to take place. It is rather a series of events and 
combinations of intrinsic and extrinsic signaling pathways that together orchestrate the 
initiation of liver regeneration. 
It is important to keep in mind that after a 2/3 PH the remnant liver lobes are subjected to 
most of the portal blood flow that previously supported the whole liver, meaning that the 
remnant liver lobes are exposed to an increase load of  nutrients and other factors, including 
growth factors. It has been seen that when the portal circulation was partly diverted from the 
liver, the regeneration was delayed and the levels of hepatocyte growth factors were 
decreased [16]. In a canine-model of PH where the whole portal blood flow was bypassed 
using a portacaval shunt, liver atrophy occurred, but once the portal flow was re-established 
the size was completely restored [17].    
 
 
1.2.2 Intracellular signals 
One of the intrinsic signaling pathways involves the activity of the urokinase-type plasminogen 
activator (u-PA), an enzyme produced by hepatocytes. A protease cascade starts where all 
steps contribute to remodeling of the extracellular matrix. Hepatocyte growth factor (HGF) 
which is a complete mitogen (see below) is also activated by u-PA and activated HGF further 
increases the expression of u-PA. Both of these above mentioned mechanisms functions as 
mitogenic signals for hepatocytes in liver and the increase in u-PA activity is the earliest 
biochemical change documented in the regenerating liver [18-20].  
Beta-catenin, another protein in the intrinsic signaling pathways of early liver regeneration, 
migrates into the nucleus very short after PH. In the nucleus it dimerizes with proteins 
belonging to the Tcf family of transcription factors thus initiating transcription of cell cycle 
associated genes [21].The presence of beta-catenin is increased in the nuclei of hepatocytes 
already 5 minutes after PH and remains there for more than 24 hours [22]. Mice lacking beta-
catenin show insufficient liver regeneration [23]. 
Yet another rapid actor is Notch, a transmembrane protein that after binding to its ligand and 
the intracellular domain of Notch is cleaved off will migrate into the nucleus. This occurs about 
15 minutes after PH and induces transcription of Notch-dependent genes. Deficient rat liver 
regeneration has been observed when Notch or its ligand has been inhibited [24]. 
 
 
1.2.3 Extracellular signals 
Extrinsic pathways (also called extra-cellular signals) can be divided in two main groups, based 
on their mode of actions. First, there are the complete mitogens that involve HGF and its 
receptor MET and EGFR with ligands (EGF, transforming growth factor alpha (TGFα), 
amphiregulin and HB-EGF)).  The complete mitogens causes enlargement of the liver in intact 
non-resected animals and are mitogenic for primary hepatocytes cultured in chemically 
defined and serum-free media.  Second, there are so called auxiliary mitogens that involve 
molecules that control the accurate timing of important transcription factors involved in 
events essential for initiation of liver regeneration, which include IL6, tumour necrosis factor 
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(TNF), norepinephrine, bile acids, leptin and more. Without any of the auxiliary mitogens the 
regeneration will be delayed but not totally impaired. Many of the signaling molecules 
belonging to both the complete and auxiliary mitogens rise in blood shortly after PH. There are 
studies showing synergistic effects between the complete and auxiliary mitogens. 
In rat cell primary cultures norepinephrine reinforces the mitogenic effects of EGF and HGF 
and also offsets the negative effect on mitosis of TGF-beta [25]. The role of TGF-beta during 
liver regeneration is intriguing and was shown to inhibit proliferation in cell culture but 
enhances at the same time the motility of the hepatocytes. TGF-beta is expressed by stellate 
cells. There is no evidence that hepatocytes express it, but hepatocytes have receptors on its 
surface responding to it and most of hepatocarcinomas produces it [26].  
 
 
1.2.4 Interleukin 6 
The IL6 is a well-known cytokine that belongs to the innate immune system and is one of the 
acute-phase proteins. It is produced by macrophages, endothelial cells and T-cells in response 
to infection and tissue injury [27]. The level of IL6 is rapidly increased in the liver after PH and 
can be detected in plasma just a few hours after surgery. This pro-inflammatory cytokine 
stimulates secretion of other acute-phase proteins produced by the liver, it stimulates B-
lymphocytes to produce antibodies and in concert with IL1, IL6 activates T-cells. Circulating IL6 
binds to a soluble receptor and forms a complex. The IL6 –receptor complex binds to gp130 
which is a receptor on the plasma membrane of cells including hepatocytes [28]. When the 
complex binds to the gp130 receptor it will lead to an activation of the JAK/STAT signaling 
pathway [29].  STAT3 will be phosphorylated by JAK, translocate to the nucleus and there 
function as a transcription activator and a mediator of expression for several genes involved in 
cell growth.  When IL6 is knocked out in mice, liver regeneration is delayed because of a 
decrease in expression of STAT3 which is a key molecule in hepatocyte proliferation [30]. 
 
The involvement of TNFα in liver regeneration was first described 1992 when neutralizing 
antibodies was used against the molecule and liver regeneration was delayed [31]. The plasma 
levels of TNFα are raised shortly after PH and by assisting in NFκB activation with an unknown 
mechanism will promote cell proliferation [32]. An overview of the induction of the signaling 
machinery after 2/3 PH in rats is outlined in figure 2. 
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Figure 2. A schematic and simplified view of the complex signaling cascade that follows a partial 
hepatectomy. A complex orchestration of several signaling molecules and their respective pathways will 
simultaneously drive the hepatocytes towards proliferation quickly after partial hepatectomy in order to 
compensate for the lost liver tissue and to restore the functional liver mass. 
 
 
 
 
1.2.5 Termination of liver regeneration  
The regeneration stops when the liver has reached 100% of its original size and can fulfil the 
demands of the organism. The mechanisms lying behind termination are not as extensively 
studied as the initiating mechanisms, but the processes seem to be as complex. There is 
evidence of an increased number of hepatocytes at the end of regeneration and that a small 
wave of apoptosis occurs to adjust the number [33].  
 
1.2.6 Role of the facultative stem cells in regeneration 
A stem cell is a cell that has the ability to continuously divide and differentiate into various 
other kinds of cells.  In the liver, hepatic progenitor cells (HPCs), also named oval cells, are 
proposed to reside within the Canals of Hering into which the bile produced by the 
hepatocytes is drained. The normal liver regenerates through proliferation of mature 
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hepatocytes, but in chronic liver injury this capacity may become lost or impaired. As an 
alternative for restoring lost liver mass the bipotential HPCs can give rise to both hepatocytes 
and biliary epithelium [7].  However, the HPCs may also be a potential source of liver cancer 
[8]. The underlying molecular mechanisms for activation of HPCs are not yet known. In 
transgenic mice an overexpression of a member of the TNF-family of cytokines was found to 
stimulate oval cell proliferation [9] and also a hepatocyte-specific deletion in a tumour 
suppressor gene was found to result in a progressive expansion of oval cells [10]. However, if 
these factors contribute to a direct stimulation of oval cells is still unclear and the exact 
mechanism remains to be further elucidated.  
 
 
 
1.3 HEPATOCELLULAR CARCINOMA 
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and accounts 
for around 6 % of all human cancers worldwide. It is the fifth most common cancer worldwide 
and the third most common cause of cancer-related death after lung and stomach cancer [11].  
The prevalence is highest in Asia and sub-Saharan Africa which can be explained by the linkage 
to the endemic hepatotrophic viruses like hepatitis B and C viruses, which both are important 
factors in the development of HCC. However, vaccination programs against HBV are currently 
going on in many parts of the world, which will reduce the risk and incidence of HCC in the 
future [12]. In the western world the yearly incidence is lower but rising where excessive 
alcohol ingestion and obesity are plausible factors to the increasing number of HCCs [13].  
Synergistic effects have been reported between obesity and alcohol abuse and the 
development of HCC [14]. Also interactions between alcohol ingestion and hepatitis C have 
been observed to aggravate the liver disease [15]. 
Other risk factors that are linked to HCC are aflatoxin-contaminated food, and inherited 
metabolic disorders like hemochromatosis and glycogen storage disease. In 80% of all cases 
HCC has developed from an underlying liver disease that has led to liver cirrhosis or chronic 
inflammation. In patients with HCV and excessive alcohol intake the risk is potentiated. The 
risk of getting HCC is 2-4 times higher for men compared with women. 
 
 
1.3.1 Pathogenesis 
 
Carcinogenesis is a multistep process 
Generally, carcinogenesis is described as a multistep process that starts in a single cell and that 
will ultimately lead to a malignant tumor. The molecular steps of hepatocarcinogenesis are not 
yet fully understood, and no dominant pathway of the development has been revealed. 
Evidence suggest that chronic liver damage and inflammation will lead to an oxidative 
environment mediated by free radicals and inflammatory cytokines that together with chronic 
repair processes may be of importance for the carcinogenic process. In experimental 
hepatocarcinogenesis on rat liver this multistep process has been defined. The first step, 
initiation, starts with formation of DNA-adducts changing the molecular structure of certain 
genes, (genetic alterations), the majority of such alterations are eliminated through the DNA-
repair machinery within the cell within the first 24 h. If cell division in a cell occurs before DNA 
repair is complete, the molecular alteration of the DNA-base can cause a false transcription 
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giving rise to genetic alterations in the daughter cell, which now carries a mutation. In the next 
step, promotion, the initiated cells will by their growth advantage over normal cells in the 
presence of a toxic promoter proliferate and by clonal expansion form pre-neoplastic foci.  
The preneoplastic cell is dependent on a promoter for further development and represents a 
reversible stage of the development providing that the promoting agent or other 
circumstances that selects for growth of initiated cells are removed, for example clearance of 
hepatitis virus or avoidance of alcohol. A promoter is any agent creating a selective pressure 
that favors the cells that have acquired a resistance to the mitoinhibitory effect of the 
promoter. The preneoplastic cells cannot yet be defined as tumour cells but rather as cells 
adapted to a toxic environment possessing a growth advantage that will allow cells to grow, 
when normal cells do not. This adaptation has been crucial for survival in toxic environments 
and is frequently seen in cancer development and classified as dysplasia or intraepithelial 
neoplasia. Eventually the pre-neoplastic cells will by further mutations lose their ability to 
reverse to normal tissue and therefore become neoplastic. Finally, in the progression step, 
multiple alterations at the genetic level will occur in the growing cells and further clonal 
expansions and selection of cells with growth advantage will give rise to cell populations with 
the malignant growth pattern and phenotype. The phenotypic alterations described in the 
preneoplastic cells are multi-genetic and complex and referred to as the resistant phenotype 
[16]. In this thesis we used the Solt and Farber model for chemically induced carcinogenesis in 
rat liver (paper II). In this model initiation and promotion are achieved using chemical 
carcinogens in combination with mitoinhibitory agents and regenerative stimuli [17].  See 
methods. 
 
Studies have shown that defective DNA mismatch repair, telomerase activation and induction 
of angiogenic and growth factors can contribute to the transformation of liver cells [18-20]. 
The knowledge of growth factor activation is incomplete but some are thought to be involved 
in one or more steps in hepatocarcinogenesis. Expression of insulin growth factor II -a factor 
that is active in the fetal liver and then silenced – has been noted in both animal models of 
liver cancer and human HCCs and was also suggested as an early marker [21-24]. During liver 
regeneration transforming growth factor alpha (TGF-α) is proposed to have a direct 
stimulating effect of DNA synthesis, and in a clinical study, 65 % of the patients was shown to 
have elevated levels of tumour TGF-α in the urine and the growth factor has in addition to that 
also been found to be overexpressed in the majority of HCCs [25-27]. In a rat study, the 
expression of TGF-α was increased and was suggested to have a promotive role in the liver 
carcinogenesis [28] . Oncogene activation of particularly the ones belonging to the ras-family 
has been found in animal hepatocarcinogenesis models whereas in humans no uniform 
pattern of activated proto-oncogenes has been seen [29-33].  
The importance to understand the growth-regulation on a molecular level is of great value for 
understanding cellular events involved in transformation of hepatocytes and may be helpful to 
improve preventive strategies and novel therapies for hepatocellular carcinoma. 
 
1.3.2 Drug metabolism 
The metabolism of drugs in the hepatocytes involves three major steps. In the first step, called 
phase 1, harmful substances are detoxified by some of the cytochrome p450 supergene family 
of proteins. This step generates reactive intermediates since CYP 450 adds a reactive group, 
often a hydroxyl radical to the compound being bio-transformed. To protect the cell from the 
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now activated compound, a phase II conjugating reaction occurs. This step makes the 
intermediate compound water-soluble to facilitate excretion from the body. Several types of 
conjugation molecules are present in the body and the reactions include glucuronidation, 
sulfation, and glutathione and amino acid conjugation. Excretion of drugs often referred to as 
phase III of drug metabolism are mediated by membrane drug pumps, in the hepatocytes 
often associated with the bile canalicular plasma membrane. 
In the resistant phenotype these drug metabolizing systems are altered, making the cells more 
resistant to toxicity and oxidative stress. The phase I, CYP450 reactions, are slowed down while 
the phase II conjugating processes are increased. As a consequence less toxic intermediates 
will form and the excretion of water soluble compounds will increase. In addition, levels of 
several antioxidants are increased such as the lipid-soluble membrane associated ubiquinols, 
the water soluble glutathione, SOD, catalase and thioredoxin to mention some. Another early 
alteration is the inactivation of p53 preventing it to enter and act in the nucleus [34]. 
P-glycoprotein also known as multidrug resistant 1 (MDR1) is an ATP-driven drug efflux pump 
with a broad substrate specificity for xenobiotics. This pump decreases drug accumulation in 
multi-drug resistant cells and contributes further to the development of resistance to 
anticancer drugs. [35]. Expression of the multidrug resistant genes MDR1 has been found in 
many cancers including liver cancer. A clinical study showed that MDR1 was overexpressed in 
patients with untreated liver cancer [36].  
Since the cancer cells have acquired efficient ways to detoxify harmful substances there is a 
challenge to develop new regimens for the treatment of HCC.  
 
Figure 3. Schematic picture of cancer development. Not surprisingly the picture of what is 
known today about HCC development displays a large heterogeneity on the basis of the genetic 
instability and  its mixed etiology [37]. However, in patients with alcohol abuse, hepatitis 
infection or certain metabolic diseases hepatic transformation occurs in the context of chronic 
liver injury, regeneration and cirrhosis, conditions which may lead to oxidative DNA damage 
and subsequently genetic alterations such as chromosomal rearrangements leading to loss of 
heterogeneity and inactivation of tumour suppressor genes, for example p53 [38]. 
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Figure 4. Chronic liver injury and chronic repair may lead to tumour development. 
The regenerative growth factors expressed during chronic liver repair, together with the complex 
environment of oxidative components and co-existing cell proliferation will together support liver 
tumour development [39]. This whole series of events may take decades from the initial infection or 
initial exposure to harmful agents until manifestations of the tumour disease. The majority of human 
liver cancers develop in a cirrhotic liver, and if an underlying viral hepatitis exists, interactions between 
the virus and the host immune reactions may lead to chronic necroinflammation. 
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Figure 5. Staging of HCC as suggested of BCLC (Barcelona Clinic Liver Cancer). Adopted from Llovet JM, 
Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003, 6;362(9399):1907-1917).  
 
 
 
 
 
1.3.3 Diagnosis and treatment  
One important problem with HCC is its asymptomatic progression; patients can go for a long 
period of time with a silent malignant disease and eventually when the tumour burden is so 
high that symptoms arise, the disease has progressed to an advanced stage. The liver has a 
profound capacity to compensate for loss of function and early symptoms are sparse and un-
specific [40]. If a tumour eventually interferes with bile ducts, serum bilirubin will increase and 
jaundice (yellowing of the eyes and skin) arise. Patients with a known chronic liver disease and 
cirrhosis are often included in surveillance programs with repeated ultrasound investigations 
to detect tumors at an early stage and possibly offer a curative treatment such as liver 
transplantation, resection or radiofrequency ablation.  
Staging of tumours is of paramount importance in order to offer the most appropriate 
treatment available. This applies to all types of cancer, but in the case of HCC, this is 
particularly difficult given the degree of the underlying liver disease in combination with the 
patient's general condition. For this purpose several staging systems have been developed, the 
most widely used of which is the BCLC (Barcelona Clinic Liver Cancer) system. 
Treatments of HCC can be divided in three groups: curative treatment, palliative treatments or 
best supportive care. The first group involves transplantation, resection and local ablative 
14 
 
treatment. The palliative treatments include transarterial chemo-embolization (TACE) and 
systemic treatment with sorafenib or internal or external radiation. The treatment in the latter 
group aims to alleviating the symptoms of the disease and increase survival. 
Patients with early diagnosed HCC may thus be subjected to hepatic resection, transplantation 
or local ablation for potentially curative purposes. Even though patients with liver cirrhosis are 
surveyed with ultrasound, the majority of tumours are still diagnosed at an intermediate or 
advanced stage [41]. Tumours discovered at an intermediate stage can be treated with 
transarterial chemoembolization (TACE) [42],  whereas to date the only treatment proven to 
prolong life for patients with advanced HCC is the multikinase inhibitor sorafenib [43].  
Sorafenib is a low weight molecule that inhibits phosphorylation of serine/threonine kinases 
like Raf-kinases and receptor tyrosine kinases such as vascular endothelial growth factor 
receptor (VEGFR) and platelet derived growth factor beta receptor (PDGFR-β) thus preventing 
cell growth promoting pathways and angiogenesis by inhibition of genetic transcription. 
Sorafenib was approved by Food and Drug Administration (FDA), in 2005 for kidney cancer and 
2007 for treatment for non-resectable HCC [44].    
 
 
 
1.3.4  Sorafenib  
1.3.4.1 Modes of action 
The signaling pathway Raf/MEK/ERK is a positive proliferative signaling cascade that results in 
the activation of ERK 1/2 and is activated by growth factors like EGF, PDGF, VGF and cytokines 
like IL6 and TNF-α. Sorafenib inhibits this cascade at the level of the serine/threonine kinase 
activity of Raf and also the receptor tyrosine kinase activity of VGFR-2 and PDGFR-b (fig 5). 
Sorafenib binds to the ATP binding site on its targets thus preventing the receptor kinases 
from binding ATP and to phosphorylate their respective substrates. There are other 
substances today that also prevent the above mentioned targets, while sorafenib is the only 
drug that also targets the Raf/Mek/Erk pathway. 
Sorafenib can function as inhibitor, antagonist and/or substrate and over 20 molecules have 
been revealed as targets for the actions of sorafenib [45] . It inhibits Raf proto-oncogenes 
serine/threonine kinases and several isoenzymes in the CYP450 family of proteins as well as 
transporter proteins like multidrug resistance-associated protein 4 and MDR1 [46, 47]. 
Moreover sorafenib is a substrate for some CYP450 and UDP glucuronosyltransferases and an 
antagonist for VEGFR2 and 3, FL cytokine receptor, beta PDGFR and Mast/stem cell growth 
factor receptor (KIT). 
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Figure 6. Schematic picture of mechanisms of the multi-kinase inhibitor sorafenib. Phosphorylation of 
tyrosine kinases of growth factor receptors are inhibited as well as inhibition of Ras in the 
Ras/Raf/Mek/ERK pathway. Inhibition of these pathways will slow down cell proliferation and 
angiogenesis.  
 
 
 
1.3.4.2 Biotransformation and elimination 
The clearance of sorafenib is primarily performed by the liver; the drug is oxidized by CYP3A4 
and glucuronidized by UGT1A9 and the elimination half-life is 25-48 hours. Sorafenib 
conjugates may be degraded in the gastrointestinal tract by bacterial glucuronidase activity 
which allows reabsorption of the unconjugated drug. The UGT1A9 is a gene that encodes for 
UDP- glucuronosyltransferase, which is an enzyme that converts lipophilic molecules to water 
soluble excretable metabolites. Five of eight identified metabolites have been found in plasma. 
Of these metabolites, the pyridine N-oxide comprises of 9-16% of the circulating analytes and 
show a potency similar to that of sorafenib in vitro. Steady state of plasma concentrations of 
sorafenib is reached within 7 days [48].  Common side effects of sorafenib are diarrhea, hand 
and foot syndrome, weight loss, fatigue and hypertension.  
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1.4 IRON 
1.4.1 The neoplastic phenotype and iron 
In many neoplastic cells iron metabolism is altered [49].  These alterations in iron regulation 
often coincide with increased proliferation and may thus contribute to disease progression 
[50]. One feature of pre-neoplastic liver cells is that despite their higher uptake, they are 
depleted in ferritin- bound iron and appear iron-free on histological sections. The turnover in 
tumours is high and they require a lot of iron but have very low levels of iron stored. The 
tumour cells increase their expression of TfR1, thus facilitating a high iron uptake to meet the 
high demands of iron in a malignant fast and autonomously growing cell. 
Iron free dysplastic foci have been described in several studies in patients with 
hemochromatosis and in animal models of iron overload [51, 52].  
One of the alterations seen in neoplastic cells are elevated levels of TfR1 indicating a higher 
demand for iron for tumour cell survival [53]. Another alteration was seen in a breast cancer 
study, where tumour cells had lower levels of ferroportin (FPN), the cellular iron exporter, and 
higher levels of hepcidin, the iron hormone, thus blocking release of iron from the cells. In this 
study there was a correlation between low levels of FPN and a bad prognosis [54].  
Ferritin is not only an intracellular molecule, but also exist extracellularly and is believed to 
deliver iron to some extent, and the levels of ferritin have been reported elevated in some 
tumour tissues and may promote angiogenesis [55, 56].  
 
 
1.4.2 Iron and iron metabolism 
As an essential trace element, iron is crucial for life and as a component of different 
metalloproteins it participates in important cellular activities. These proteins include 
hemoglobin, myoglobin, catalase and cytochrome P450 [57]. Iron can also act as a cofactor of 
metalloproteins and is required in enzymatic processes involved in metabolism, cell respiration 
and DNA-synthesis [58]. The iron needed to meet demands from cells and tissues is 
transported to the cells as transferrin-bound iron in the plasma. The level of iron in plasma 
mirrors the absorption of dietary iron by duodenum and also the release of iron mainly from 
macrophages that stores iron. The macrophages in the spleen break down red blood cells and 
hence iron can be recycled. The total amount of iron that is lost and has to be added is 1 
mg/day for men and 1.5-2mg/day for women. Most of the 4-5 g iron bound to cellular 
enzymes or in iron stores is recycled. There is no excretion pathway more than a small amount 
that is lost through shedding of cells of the skin and the mucosal cells of the gastro-intestinal 
tract.  
The uptake of iron starts on the brush border of the enterocytes in duodenum where inorganic 
Fe3+ iron is reduced to Fe2+. The ferrous iron is then transported into the enterocyte via the 
divalent metal transporter 1 (DMT1). Once inside the cell the iron can bind loosely to iron 
chelators like citrate or more tightly to ferritin. Iron is reconverted into the ferric form, by the 
ferroxidase property of ferritin [59]. For transportation to the bloodstream ferrous iron is 
transported via the transmembrane transporter ferroportin (FPN) and is directly converted to 
the ferric form by heaphestin outside of the basolateral membrane of the enterocyte. After 
oxidation the ferric iron is bound to transferrin for further transportation [60]. 
The uptake of iron from blood to hepatocytes can occur in several different ways [61].  The 
most important iron-binders are transferrin and citrate and the uptake of iron from transferrin 
17 
 
is well understood involving TfR1 and 2. However, the mechanisms of non-transferrin (NTBI) 
bound iron is still poorly understood [62].  
 
1) Receptor-mediated endocytosis of transferrin via the high affinity receptor transferrin 
receptor 1 (Tfr1). First, diferric transferrin binds to the receptor at the cell surface of the 
hepatocytes [63]. Clusters of bound receptors are formed and the cell membrane is 
invaginated and pinched off and results in clathrin-coated vesicles that will fuse with 
intracellular vesicles. At this point endosomes with low pH (5,5) have been formed and the 
iron can be released from its carrier [64]. The iron is reduced to the ferrous form, enters the 
cytosol and is bound to ferritin for storage. The receptor-apotransferrin complex is recycled to 
the cell surface and the apotransferrin is released.  
 
2) The second way most likely involves Tfr2 and is a low-affinity process with endocytosis of 
diferric transferrin, delivery of the iron to the cell and then a recycling event of transferrin back 
to the plasma membrane similar to Tfr1 [65]. TfR2 seem to have an iron-sensing and hepcidin-
modulating role rather than iron uptake [66].  
 
3) Fluid-phase endocytosis. Transferrin-bound iron can also be picked up by a non-endosomal 
pathway, something that was seen in isolated hepatocytes [67]. This pathway involves a 
NADH-dependent oxidoreductase for reduction of ferric iron. The electron flow across the 
membrane is leading to a lowered pH locally at the cell-surface, reducing the affinity of iron to 
transferrin and ferrous iron crosses the cell membrane by a mechanism that is still unknown. 
 
4) The current model for the cellular uptake of NTBI involves a ferrireduction by trans 
membrane ascorbate (Asc) cycling. Extra cellular Asc reacts with NTBI resulting in Fe2+ and 
dehydroascorbate. The divalent iron is then taken up by the cell via DMT1 or another ferrous-
selective transporter called Zip14 [68-70].   
 
5) Heme iron is taken up by the enterocytes via the heme carrier protein (HCP1). Within the 
cell iron is released from heme via the action of the enzyme heme oxygenase [71]. 
 
6) Hepatocytes can also be provided with iron from circulating ferritin molecules by specific 
receptors [72]. 
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1.4.3 Hepcidin, the master iron-regulatory hormone 
Since there is no way to excrete and get rid of iron from 
the body, the uptake must be strictly regulated. In 2004 
the peptide hormone hepcidin was discovered and is today 
recognized as the major regulator of iron homeostasis and 
metabolism. Hepcidin is synthesized by the liver and is 
circulating in the plasma after its secretion. The peptide 
reduces both uptake and release of iron by binding to the 
iron efflux protein ferroportin (FPN) on enterocytes and 
macrophages leading to its internalization and blocking 
iron export. Expression of hepcidin is induced by high iron 
levels or as a response to inflammatory cytokines such as 
IL6 [73, 74]. 
The iron-sensing pathway of hepcidin induction is complex and involves Tfr1 and 2, bone 
morphogenetic proteins (BMPs), the hemochromatosis gene (HFE), hemojuvelin (HJV) and 
Smad4. A central regulator in this pathway is HJV which is an iron-specific ligand of the BMP 
receptor leading to sensitization of BMPs [75]. Transcription of hepcidin is regulated via BMPs 
induction of Sma- and Mad related protein 4 (SMAD4) which in turn regulates a cascade of 
several Smad proteins [75].  
The HJV/BMP/SMAD4 pathway interacts with Tfr1, Tfr2 and HFE. In collaboration with Tfr1 
and 2, HFE detects the levels of holotransferrin in plasma and when iron levels are high iron 
will bind with high affinity to Tfr1, where upon HFE can interact with Tfr2. This interaction on 
the cell surface of the hepatocyte will increase the BMP/SMAD4 signaling and lead to 
activation of transcription of hepcidin [76]. 
The inflammatory pathway of hepcidin transcription induction involves interleukin 6 (IL6) and 
transcription factor of activation 3 (STAT3). There are evidence from several studies of at least 
one inflammatory cytokine to induce activation of transcription of hepcidin in both cells and 
animals [73].  
Figure 7. Uptake of iron in 
duodenum and transferrin-bound 
uptake of iron in hepatocytes. First 
ferric iron is reduced by DCytb on the 
surface of the enterocytes of the 
duodenum to ferrous iron to permit 
transport over the cell membrane 
via DMT1. In the enterocyte iron is 
either converted to the ferric form 
and stored in ferritin molecules or 
transported to the bloodstream via 
ferroportin. Iron is directly oxidized 
by heaphestin and bound to 
transferrin for further transport to 
the cells in the body.  
Each transferrin molecule can carry 
two ferric iron ions. The diferric 
transferrin binds to Tfr1 on the cell 
surface of the hepatocytes and is 
invaginated via endocytosis; the pH 
in the endosome is lowered by an 
ATP driven membrane proton pump 
which facilitates the release of iron 
from its transporter. The iron is 
reduced and passes through the 
membrane into the cytosol where it 
is stored in ferritin or utilized for 
cellular processes. 
 
 
19 
 
 During the acute-phase response of inflammation IL6 is released from macrophages and 
Kupffer cells, it binds to its receptor on hepatocytes and a signal goes via JAK/STAT to STAT 3 
and an activation of transcription of hepcidin is induced [77]. Cross talking between the 
JAK/STAT and the SMAD pathways have been suggested in fetal brain, and may be a possible 
process in the liver as well [78]. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Simplified picture demonstrating the induction of hepcidin transcription via the  
1) inflammatory pathway involving IL6 and JAK/STAT and 2) the iron sensing pathway that involves 
diferric transferrin, Tfr1 and TfR2, HFE, BMP/HJV and SMAD4. Under normal conditions the interplay 
between these pathways are fine-tuned and strict. 
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Figure 9. A) Inflammatory induction of hepcidin via IL6 will lead to internalization of the iron exporter 
ferroportin (FPN). Hepcidin binds to FPN and degrade the protein leading to a block of release of iron 
from the enterocytes to the bloodstream and block of release of iron from macrophages. The levels of 
iron in plasma will decrease. B) Deactivation of induction of transcription of hepcidin. The right side in 
the picture shows an impaired expression of hepcidin due to mutations in HJV or HFE, as in hereditary 
hemochromatosis. The iron sensing pathway of transcription of hepcidin will be disturbed and the 
decreased expression of hepcidin will lead to iron overload.  
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1.4.4 Iron storage and regulation  
Although essential for life iron possess toxic properties in its free form and therefore 
organisms are equipped with a complex and carefully regulated machinery for storage of iron 
and regulation of iron homeostasis. Free iron is highly toxic to the cells and therefore the 
uptake as well as the storage is tightly regulated to avoid the fact that free iron can act as a 
catalyst in the formation of free radicals from reactive oxygen species (ROS). In the so-called 
Fenton reaction a hydroxyl radical is formed from hydrogen peroxide catalyzed by ferrous iron 
[79, 80]. 
The Fenton reaction: 
 
Fe2+ + H2O2   Fe
3+  + OH- + •OH 
 
Ferritin, a protein synthesized by the liver is the major iron storage molecule within the cell, 
predominantly found in the cytoplasm and in lysosomes. Apo-ferritin consists of 24 iron 
binding subunits. Each ferritin molecule can therefore harbor thousands of ions of ferric iron 
[81]. The size of the ferritin is around 450 kDa and it is composed like a shell that surrounds a 
ferrihydrate moiety [82]. In addition ferritin has a ferroxidase activity and can accordingly 
convert ferrous iron to its ferric form. 
 The iron can also be bound to iron-regulatory-proteins (IRP) which becomes activated in iron 
deficiency and when iron demands are high will bind to iron-responsive elements (IRE) of 
mRNAs. This is a post-transcriptional regulation of iron uptake and storage. When intracellular 
iron stores are scarce,  activated IRP binds to iron-regulatory elements (IREs) which stabilizes 
the mRNAs of Tfr1 and DMT1 but blocks the translation of mRNAs of ferritin and FPN [83]. 
 
 
1.4.5 The role of iron in cancer development 
Despite its necessity for all cells iron in excessive amounts may lead to fatal toxicity. Since the 
liver is the major site of iron storage it is also in particular affected to the toxic effects of 
excessive iron. The catalytic process by which the toxic effects of iron occurs involves the 
enhanced formation of hydroxyl radicals via the Fenton reaction and may lead to peroxidation 
of membrane lipids of the lysosomes, the endoplasmic reticulum and the mitochondria and 
leading to organelle dysfunction and cell death [84-87]. In addition studies suggest that free 
iron has a direct hepatocarcinogenetic effect by the formation of ROS and oxidative injuries 
that are both mutagenic and carcinogenetic [88].  See more about free radicals under that 
section on page 24. 
In disorders, genetic or acquired, with disturbed iron regulatory machinery, patients are at risk 
for iron overload of parenchymatous organs like the liver. This is seen in patients with 
hereditary hemochromatosis (HH) which is the most common cause of iron overload in 
individuals of Northern European origin.  Excessive amounts of iron are absorbed from the gut 
and are primarily stored in the hepatocytes [89-91]. Several mutations of the HFE have been 
revealed and the most common in hereditary hemochromatosis in Sweden and Northern 
Europe is the Cys282Tyr mutation [92, 93]. This mutation renders an altered protein prevented 
to reach the cell surface. Iron regulation is hereby disrupted and results in altered iron-sensing 
signaling, hepcidin deficiency and iron overload [94].  Moreover, mutations in the HJV gene 
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leading to an ineffective protein have been shown to decrease hepcidin synthesis and cause a 
severe iron overload (juvenile hemochromatosis) [95]. 
Secondary iron overload implicates hepatic iron overload as a consequence of repeated 
transfusions or as a result of increased iron absorption in patients with thalassemia major or 
sideroblastic anaemias. In addition secondary iron overload  is also seen in disorders in 
porphyrin metabolism like porphyria cutanea tarda [96]. 
 
 
 
1.5 OXIDATIVE STRESS AND FREE RADICALS  
Atoms or molecules with one or more unpaired electrons are called free radicals. Molecules 
with free electrons are reactive and can participate in reactions to form new molecules, a 
prerequisite for metabolism and life. A reactive compound can bind to cellular molecules and 
compromise the structure or function of cellular organelles. Free radicals are naturally formed 
as by-products in the cellular metabolism of oxygen. Some cells can use free radicals in their 
mission to degrade foreign compounds and constitute a part of the immune system for the 
destruction of invading microorganisms. In biological systems, functions and mechanisms are 
double-edged swords, as in the case with free radicals, whilst being a part of the immune 
system against invading microorganisms; they may cause serious cellular damage to the body. 
They are highly reactive and by their capability to damage DNA, proteins, lipids or 
carbohydrates, free radicals by causing cell damage or cell death may contribute to the 
development of chronic disease like cancer and heart disease [97, 98]. 
In addition to the internally formed radicals exogenous compounds in our environment can be 
activated and reactive as in cigarette smoke, drugs, solvents , food additives, industrial 
pollution. In the process of cellular elimination of the exogenous compounds reactive 
intermediates will be formed. Also exposure to UV-light and radiation form reactive 
compounds of natural compounds in the cell. The most important free radicals in biology are 
the superoxide (O2
- ) and hydroxyl radical (OH•.) 
 
The hydroxyl radical is formed in the Fenton reaction together with Fe3++ Or Cu2+  but can also 
be formed from superoxide and hydrogen peroxide via the  iron-catalyzed Haber Weiss 
reaction: 
 
 
1) Iron salt will be reduced by O2 
- 
 :  Fe
3+ +  O2 
- 
      Fe
2+ +  O2 
2) A hydroxyl radical forms via the Fenton reaction Fe2+ +  H2O2   Fe
3+ +  OH- + •OH 
3) Net reaction = the Haber-Weiss reaction O2 
- 
  +  H2O2    O2 + OH 
- + •OH 
  
                    Fe3+      Fe2+  
 
 
1.5.1 Anti-oxidant defense 
There are several ways in which unpaired electrons can be scavenged and these have been 
divided into three different levels of defense. The first level involves prevention of radical 
formation and to this group a number of proteins, enzymes and enzyme systems belong, such 
23 
 
as superoxide dismutase (SOD), glutathione peroxidase (gpx), catalase, glutathione, members 
of the thioredoxin systems and metal-binding proteins. In the second level we find molecules 
that act to prevent and restrict chain formation and propagation; carotenoids, glutathione, 
ubiquinols, vitamin A, C, E and uric acid. And in the third and last level of defense there are 
proteins that perform excision and repair of damaged parts of molecules; lipases, peptidases, 
proteases, transferases, and DNA-repair enzymes among others. 
Examples of mechanisms to scavenge free radicals: 
Superoxide which is the most common free radical is converted to peroxide and oxygen by 
SOD through the following reaction: 
2O*2 +2H
+  H2O2 + O2 
 
 
Hydrogen peroxide formed is further detoxified by GSH-px which reduces it to water as 
follows: 
H2O2 + 2GSH  GSSG +2H2O 
 
The hydroxyl radical (•OH) is highly reactive and is stopped by scavenging of endogenous 
antioxidants such as glutathione and melatonin or via dietary sources of anti-oxidants like 
vitamin E or mannitol [99]. 
Thiols are a class of organic compounds containing a sulfhydryl group (SH) composed of a 
sulfur and a hydrogen atom bound to a carbon. This group is also known as the thiol group and 
as the functional group of the amino acid cysteine it has a very important role in biology. 
When thiol groups of two cysteine residues meet they may form a cystin unit with a disulfide 
bond via an oxidation reaction. If the two residues belong to the peptide chain, the disulfide 
bond will contribute to the tertiary structure of that protein. If they belong to different 
proteins these bond can form quaternary structures and multi-unit proteins. Thiol groups in 
the active site of enzymes can contribute to their catalytic activity by forming non-covalent 
bonds with substrates. On the cell surface and in extracellular compartments many proteins 
that are rich in disulfide bonds reside. Redox cycling in the cell is of fundamental significance 
for the function of the cell but at the same time it is important to keep the intra cellular 
environment reduced. 
R-S-S-R +2H+  + 2e
-   RSH  +  RSH 
 
 
1.5.2 The thioredoxin and glutaredoxin systems 
 
As disulfide bonds between proteins tend to increase during oxidative stress the thioredoxin 
and glutaredoxin systems function as electron donors in order to reduce these bonds.  
Both systems belong to the enzymatic defense against oxidative stress and are well studied 
and characterized in biology and their activity and expression are proven to be induced during 
oxidative stress [100].  They are ubiquitously expressed proteins belonging to the thioredoxin 
superfamily of proteins. One of the features this family shares is the three dimensional fold; 
the thioredoxin fold with a structural conserved active site motif containing Cys-X-X-Cys [101-
103].  
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1.5.2.1 Thioredoxin 
Thioredoxin is a fairly small redox protein and forms together with NADPH and thioredoxin 
reductase the thioredoxin system which is a fast thiol reductant and is expressed in all living 
organisms. It´s efficacy is built on the fast reaction between reduced thioredoxin and disulfide 
bridges in substrates. This reaction gives oxidized thioredoxin which in turn is reduced by 
NADPH and thioredoxin reductase (TrxR). 
 
 
 
In addition to the reducing feature of the thioredoxin system, it is also involved in a variety of 
biological functions like cell proliferation, DNA-synthesis, cell signaling and apoptosis [104-
106].  
In humans two isoforms of Trxs have been found, the cytosolic form Trx1 that can translocate 
to the nucleus and the mitochondrial form Trx2 (18kDa) and they are both essential proteins. 
Knock-out experiments in mice led to embryonic lethality [107, 108]. The two forms are 
encoded by different genes. Thioredoxin 1 is compact and globular shaped with a mass of 12 
kDa, and was isolated from Escherichia coli in 1964 [105]. It is composed of a twisted β-sheet 
with five strands and has on the surface four α helices and the three dimensional shape have 
been shown with both nuclear magnetic resonance and x-ray crystallography [109].  
Thioredoxin reductases are homo-dimeric selenoproteins and belong to the pyridine 
nucleotide-disulfide oxidoreductase family.  The size of the dimer is 112 kDa and they are the 
only enzymes capable of reducing the active sites of Trxs. Their N-terminal active site is a 
conserved sequence: Cys-Val-Asn-Val-Gly-Cys and in addition they also have a C-terminal 
selenium containing active site where thioredoxin as well as other substrates are reduced.  
 
1.5.2.2 Glutaredoxin 
The glutaredoxin system consists of glutathione (GSH), glutathione reductase (GR), 
glutaredoxin (Grx) and NADPH. Four different glutaredoxins have been found in humans so far, 
they are small enzymes with oxidoreductase activity and possess several important biological 
functions in the redox cell signaling. It catalyzes the reduction of disulfide bonds in proteins 
and mixed disulfide bonds with GSH by glutathionylation and de- glutathionylation. They are 
oxidized by different substrates and reduced via the oxidation of glutathione which is 
regenerated by glutaredoxin reductase.  
Depending on how their motives are constructed, Grxs can be divided to the dithiol (Cys-XX-
Cys) and the monothiol (Cys-XX-Ser) Grxs. The dithiol functions by using both the cysteines in 
the active site in order to reduce disulfides whilst the monothiol variant uses the cysteine in 
the N-terminal active site for the reduction of GSH mixed disulfides [110].   
 
The first discovered was Grx1 which is localized to the cytoplasm and is involved in DNA 
synthesis by its reduction of ribonucleotide reductase (RNR). Its mass is 12 kDa and the 
conserved N-terminal active site consists of two redox active cysteines (Cys-Pro-Tyr-Cys). As 
Trx1, Grx1 has been shown to be secreted and is suggested to possess extracellular functions 
[111]. 
 
Trx-(SH)
 2
 + protein-S
2
                        Trx-S
2 
+ protein-(SH)
 2
 
NADPH + H⁺ + Trx-S
2
                          NADP ⁺ + Trx-(SH)
 2
  
TrxR 
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Grx2 was the first Grx identified as an iron-sulphur containing member of the Trx-fold super 
family. The role of the iron-sulphur cluster is to coordinate the regulation of the activity of 
Grx2 in complex with glutathione. As a homodimer Grx2 is inactive,  and in presence of one-
electron oxidants or reductants the 2Fe-2S cluster will be disrupted leading to monomerization 
and activation of the enzyme [112, 113]. Unlike the other Grxs, human Grx2 is a substrate for 
TrxR and NADPH and can therefore use electrons provided by both systems [114].  
Three splice variants of Grx2 have been discovered so far: Grx2a residing in the mitochondria, 
Grx2b was localized to the nucleus and the third form Grx2c has been found in several cell 
lines and in testis. [115, 116]. It is not clear whether or not the splice variants are present in 
human livers. The antibodies used for IHC in this thesis do not distinguish between the three 
splice variants. 
Grx3 PICOT is a monothiol iron-sulphur-binding protein localized just beneath the plasma 
membrane and has a role in the regulation of signal transduction in the activation of immune 
cells and may also exhibit a response to ROS and RNS [117]. This redox protein was shown to 
be induced during oxidative stress in mice and a deletion resulted in early embryonic death 
suggesting a defective cell cycle progression during late mitosis [118].  
The last Grx found is Grx5 which is located in the mitochondria and is a member of the Fe/S 
cluster assembly machinery. Simplified this machinery is a step wise process that starts with 
the formation of a 2Fe-2S cluster on a scaffold protein via an electron transfer chain. The 
cluster is released from this scaffold protein and is then transferred to apo-proteins with the 
help of chaperones and the Grx5. Subsequently a 4Fe-4S cluster is generated and inserted in 
target apo-proteins. Defects in this assembly system lead to increased iron levels and 
mitochondrial iron accumulation [119].  
 
1.5.2.3 The role of thioredoxin and glutaredoxin systems in neoplasia and cancer 
The thioredoxin system is involved in control and regulation of activity of several transcription 
factors, and has been proposed to exhibit a role in cell growth and overexpression of Trx has 
been observed in a variety of cancers, including lung cancer, pancreatic cancer, stomach 
cancer, gallbladder cancer colorectal cancer and squamous cell carcinoma of the tongue [120-
126]. 
Moreover, in cell culture, increased expression of Trx1 has been shown to be associated with 
increased VEGF expression and enhanced tumor angiogenesis [127].   
Studies of the role of glutaredoxins in cancer have revealed an association with Grx1 and 
pancreatic cancer and basal cell carcinoma [122, 128]. In lung and colon-cancer over-
expression of Grx3 have been seen [129]. The enzyme TrxR1 was overexpressed in a rat study 
of neoplastic lesions [130]. 
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1.6 SELENIUM 
 
Selenium is an essential trace mineral incorporated into several proteins of which biological 
features is important for several physiological functions. In humans, 25 selenoproteins have 
been identified so far being involved in cell growth, differentiation and cell death [131, 132].  
They also possess antioxidative properties preventing the cells from oxidative damage of free 
radicals. Moreover, selenoproteins are important in the immune system and assist in the 
regulation of thyroid function [133, 134].   
Examples of selenoproteins are glutathione peroxidases, thioredoxin reductases, and 
iodothyronine deiodinases. 
Selenium was discovered by the Swedish chemist Jöns Jacob Berzelius in 1818 [135]. It was 
found to have similar properties with sulfur, and is placed at position 34 in the periodic system 
and can exist in five different Valente states: -2, 0, +2, +4 and +6. The inorganic forms of 
selenium includes selenite (SeO3 
2- ), selenate (SeO4 
2- ) and selenide (Se 2-) which differs in the 
oxidation state. Inorganic selenium is found in the soil and is taken up via plants which 
incorporate selenium into organic forms like selenomethionine (SeMet), selenocystein (SeCys) 
and selenomethyselenocystein (SeMSC) which are subsequently transferred to grazing animals 
[136]. Because of geographical variations of selenium content in the soil over the globe there 
are big variations of the levels of bioavailable selenium in food. Even though selenium is 
essential for living organisms and deficiency will lead to pathological conditions it is also highly 
toxic in high levels. 
Dietary main sources of selenium are: nuts, cereals, meat, kidney, mushrooms, fish (tuna), 
eggs and seafood (crabs and lobster) [137].  
 
 
1.6.1 Selenium metabolism 
The metabolism of selenium compounds and formation of selenoproteins has been thoroughly 
investigated. The uptake of organic Se is preferentially in the SeMet form which is converted 
into SeCys within the body and used for the synthesis of selenoproteins after formation of a 
Secis-element [138, 139]. Selenocystein is the main form of organic Se in our bodies. The 
inorganic and the organic Se are metabolized via two different pathways with hydrogen 
selenide (Hse-) as the common key metabolite used for selenoprotein synthesis or excretion 
[140] (Fig. 10). 
Elimination of selenium at normal selenium levels is usually via feces or urine after 
methylation, but volatile dimethylselenide is exhaled via the lungs. The exhalation route of 
eliminating Se-levels is considered to be the major pathway when Se is ingested in toxic doses. 
Urine excretion is usually as selenosugar that is synthesized directly from selenide or in case of 
high selenium levels, from trimethylselenonium ion [140]. 
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Figure 10. A schematic presentation of the selenium metabolism. Hydrogen selenide, the provider of Se 
to all selenoproteins, will together with ATP form monoselenophosphate via the activation of 
selenophosphate synthetase. The metabolism of inorganic selenium starts by reduction of selenate to 
selenite which is performed by GSH mediated by the Trx or Grx systems. Selenite is then further reduced 
to selenide of these systems and of thiols [141]. Selenite can also be reduced by a non-enzymatic 
mechanism affected by free cysteines [142]. In addition, selenite can be reduced to HSe- via the 
intermediate glutathione conjugate GSSeSG also in the presence of GSH [143]. The both organic 
compounds SeCys and SeMSC will be cleaved by the enzyme β-lyase to selenide and methylselenol. 
Methylselenol is converted to selenide via the action of demethylation and note that selenide can be 
methylated back to methylselenol in order to release selenium from the organism either through 
exhalation or via excretion in urine or feces to protect the organism from surplus of selenium [144, 145]. 
 
 
The recommended daily intake of selenium is based on the selenium concentration sufficient 
to saturate the selenoprotein glutathione peroxidase (GPx) and is set to 55 µg for healthy 
adults [146]. However, during pregnancy and breastfeeding the daily requirement rises to 65-
75 µg.  In Sweden the selenium content in the soil is low so here the daily dose recommended 
is suggested to 100-200 µg. The distribution of selenium between the tissues after blood 
transportation occurs in a hierarchical manner, the brain tissue being the organ with the 
highest demands followed by skeleton muscle and thirdly liver tissue. As a consequence of this 
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hierarchy, the brain will conserve selenium most efficiently in situations when the selenium 
levels are insufficient [147, 148]. 
Intoxication of selenium involves hair and nail loss, garlic smelling breath, tachycardia and 
respiratory disorders because of pulmonary edema and death [149]. 
Symptoms of deficiency involve severe cardiomyopathy seen in children and young women 
with Keshan disease in certain areas in China where the selenium content in soil is extremely 
low. Another disorder is the Kaschin-Beck disease which is a degenerative joint-disease. In 
recent years a whole spectrum of disorders related to inherited disturbances in the selenium 
utilization, transport, and metabolism have been done and this field is expanding [150].  
Deficiency of Se, may also lead to serious disturbances in human health and more than 40 Se-
deficiency related conditions have been reported so far, wherein cancer is one of them. 
Studies have shown an association with lower serum contents in cancer patients compared to 
healthy controls [151, 152].   
 
1.6.2 Selenium and prevention of cancer  
Multiple epidemiological human and prospective animal studies have investigated the 
relationship between selenium and cancer. Associations between low serum contents in 
cancer patients have been noted compared to healthy controls and  a relationship between 
low levels of Se content in food and risk for cancer and related mortality rate have been 
observed [151, 152].  There are more than 100 animal studies in which a preventive effect of 
selenium on different cancer types has been observed and moreover, there are several human 
studies that support these observations.  
 
Selenium in the prevention of human cancers is discussed in a review by Fernandes and 
Björnstedt from 2010 [153]. The underlying molecular mechanisms of the tumor preventive 
effects of selenium are not fully understood but several mechanisms have been proposed so 
far. These include anti-oxidative effects mediated by selenoproteins, stimulation of DNA-repair 
and induction of apoptosis in preneoplastic cells. The role of selenoproteins in tumour 
prevention is not known but some redox active selenoenzymes such as thioredoxin peroxidase 
and glutathione peroxidase have been extensively studied [132].  The antioxdative effect is 
proposed to be mainly preventive, thereby affecting the very early stages of carcinogenesis 
[154]. Selenoproteins play a central role in maintaining the redox homeostasis of the cell and 
are involved in all three levels of antioxidant protection against both ROS and RNS. It has been 
found that selenoproteins enhance DNA repair and cell integrity via protection against ROS, 
and that SeMet can induce DNA repair in human fibroblasts in vitro and also regulate DNA 
chain break control, and reduce aberrant crypt foci in colorectal tissue in rats.  
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2 PRESENT INVESTIGATION 
2.1 AIM OF THE STUDY 
 
This thesis was based on four separate projects. Three projects involve rat liver studies on 
various aspects of regenerative and neoplastic cell proliferation and the last study was 
performed on human liver from patients with hepatocellular carcinoma or liver metastases 
from colorectal cancer where the expression of redox proteins in tumour and surrounding liver 
tissue was studied.  
 
The overall aim of the thesis was to characterize the role of iron during liver regeneration, to 
study the effects of two anti-cancer compounds (sodium selenite and sorafenib) on 
regeneration following liver resection in rats, and to evaluate redox enzyme expression in 
regenerative and neoplastic growth, as well as their expressions in human liver cancer. 
 
The specific aims of the study were: 
 
  
 To characterize gene expressions of the different pathways involved in hepcidin 
regulation after partial hepatectomy, until liver regeneration is complete (paper I) 
 
 To study the effects of sodium selenite on regenerative vs. neoplastic liver cell 
proliferation in rat (paper II) 
 
 To investigate if TrxR1 is a constitutive tumour marker or an unspecific marker for 
cell growth in rat liver (paper II) 
 
 To study the effects of the anticancer agent sorafenib, a multikinase inhibitor, on 
normal liver regeneration after partial hepatectomy in rat  (paper III) 
 
 To evaluate if redox protein (thioredoxins and glutaredoxins) expressions correlate 
to clinical features in human HCC, and if they can be used as prognostic markers after 
liver surgery for HCC (paper IV) 
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2.2 REMARKS OF THE METHODOLOGY 
2.2.1 Animal models 
2.2.1.1  Partial hepatectomy (used in paper I, II and III). 
In the first three papers in this thesis, we have used a rat model for 2/3 partial hepatectomy. 
This is a reliable and standardized procedure as far as timing and amount of the liver removed 
is concerned, and the animals recovered quickly after the procedure.  
Male Fischer-344 rats, purchased from Charles River, Germany, were first allowed to 
acclimatize to their new environment one week prior to the experiments. They were fed a 
standard chow diet and housed in the animal facility in a 12 hour light-dark cycle where 
temperature, humidity and ventilation were controlled according to international standards. 
Partial hepatectomy was performed under general anesthesia with isoflurane. An incision was 
made in the abdominal wall and the two main liver lobes were made to pop out by a slight 
pressure on either side of the abdomen. After placing a ligature around the blood vessels, the 
two lobes were removed.  The peritoneum and abdominal wall were sutured, and Marcain 
was administered as a pain killer before the skin was closed using clamps. In the sham-
operated animals the abdomen was opened, and was gently pressed without any removal of 
the liver lobes.  
In project I the PH model was used without any other treatment and three animals was 
sacrificed from the PH group and the sham operated control group at the following time 
points: 0 h, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 48 h, 72 h, and 1 w, 2 w and finally 3 weeks after 
surgery.  
 
2.2.1.2 The resistant hepatocyte model for hepatocarcinogenesis 
This model called the “Resistant Hepatocyte model” (RH-model), was originally described by 
Solt and Farber was used in paper II, with slight modifications [17, 155]. In short: The RH-
model is a synchronized model which makes it possible to study the three consecutive 
processes in the liver tissue during carcinogenesis, initiation, promotion and progression. The 
initiation and promotion steps consist of administration of a necrogenic dose (200 µg) of 
diethyl nitrosamine (DEN) followed after two weeks by administration of 2-
acetylaminofluorene (2-AAF) and PH. 2-AAF is a strong mitoinhibitor but initiated cells have 
acquired resistance to its mitoinhibitory effects. During promotion only the hepatocytes 
resistant to the mitoinhibitory effect of 2-AAF will be able to respond to the mitogenic signals 
induced by the hepatectomy in the presence of the promoter. Through this procedure, the 
resistant cells have a growth advantage over the non-resistant cells and grow in a clonal way 
to form preneoplastic foci and nodules. During progression when administration of the 
promoter is stopped, most lesions re-model to normal liver phenotype over time. In a small 
subfraction of the nodules (less than 1%), clones of cells will appear that are able to grow in 
the absence of the promoter. In these persistent lesions changes will occur that during the 
progression phase, giving rise to malignant tumors. 
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2.2.1.3 Treatment of the animals 
Selenium and PH: 
In paper II two different experimental rat liver models were used, the resistant hepatocyte 
model for liver cancer development, and the model for rat liver regeneration after partial 
hepatectomy. In each experiment one group of animals were treated with sodium selenite in 
the drinking water and compared to one group drinking tap water. The selenium treated 
groups were administered 5 µL/mL sodium selenite in the drinking water as illustrated in Fig. 
11. At time points indicated in the figure three animals per group were sacrificed and livers 
and blood collected. The dose of sodium selenite was chosen according to earlier studies 
where a tumour preventive dose of sodium selenite was titrated [156].  
 
 
 
 
 
 
Figure 11. This protocol 
shows how the 
treatments in the studies 
were performed.  
A) In the cancer model 
animals were treated 
with sodium selenite 
during the progression 
phase and animals were 
sacrificed at 3, 6, 9 and 12 
months.  
 
 
 
B) In the PH model 
without any neoplastic 
nodules animals were 
given sodium selenite one 
week prior to PH and until 
the liver regeneration was 
completed. Animals were 
sacrificed at indicated 
time points. 
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Sorafenib and PH 
For assessment of toxicity, the animals were subjected to pH and were divided into three dose 
groups (5, 10 and 15 mg/kg body weight) and were then treated daily with sorafenib for one 
week before surgery. Four animals per group were sacrificed at 16, 20 and 24 hours after 
surgery. Four animals per group were sacrificed after one week of treatment and without PH.  
The dose 5 mg/kg body weight was chosen for the second part of the sorafenib study where 
the animals were treated daily one week before PH and were then divided in three groups. 
The first group received the vehicle Cremophor-ethanol solution after PH the second received 
sorafenib in Cremophor ethanol until 3 days post-surgery and the last group received 
sorafenib in Cremophor ethanol continuously until 14 days after surgery. Four animals from 
each group were sacrificed at the time for PH and then at the following time points: 16, 20, 24, 
48 and 72 hours and at 5, 7, 10 and 14 days post PH. The time-points were chosen to capture 
the peak of proliferation that occurs at 18-72 hours and also to investigate the effects of 
sorafenib in the later stages of liver regeneration and until it is completed at 14 days. 
Sorafenib tosylate (BAY 54-9085, Bayer Healthcare Pharmaceuticals, Montville, NJ) was 
dissolved in a 50% Cremophor EL (Sigma Cat. No 5135) /50% ethanol mixture diluted with 
water in the distribution 12,5% Cremophor EL/12,5% ethanol/75% water. The mixture was 
administered daily in a volume of 250 µL/100 g body weight by oral gavage. 
 
Administration of BrdU 
The administration of the synthetic nucleoside BrdU was done in two ways, in project II the 
animals got an osmotic mini-pump inserted right under the skin three days before sacrifice and 
in paper III BrdU was injected two hours before sacrifice. The shorter time between 
administration and sacrifice in the latter case was because we wanted to capture a small 
window for the proliferation analysis. 
BrdU was incorporated to DNA in replicating cells replacing thymidine. By using specific 
antibodies against BrdU quantification of the number of proliferative cells in liver tissue 
sections could be done with immunohistochemistry. 
 
2.2.2 Tissue sampling 
 
The rat livers were sliced immediately after sacrifice and either snap-frozen in liquid nitrogen 
for gene and protein analysis, or put in 4% formaldehyde, routinely processed and embedded 
in paraffin for immunohistochemical stainings. The sampling of the human liver was done in 
the same way except from a little longer processing time.  
 
2.2.3 Quantitative Polymerase Chain Reaction 
 
For analysis of gene expression real time-QPCR was used in paper I, III and IV. Gene-specific 
primers were designed and where possible these were exon-spanning for high specificity. For 
detailed information on primer sequences and individual steps during the amplification 
process, please see the methods section in each project. 
In paper I we used a system that is built on gene specific primers and a TaqMan probe and in 
paper III and IV we used the system based on gene-specific primers and SYBR-green.  
The TaqMan system is based on a fluorogenic sequence-specific probe that will detect a 
specific PCR-product as it accumulates during the cycles while the SYBR green system involves 
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a dye that intercalates with any double stranded DNA. Post PCR steps are required when the 
SYBR green method is used involving sequencing of the PCR product for detection of false 
positives, a step that is unnecessary using the TaqMan method. However, the SYBR- green 
method involves higher sensitivity and is also a cheaper method to set up the lab in 
comparison to the TaqMan-method. 
 
2.2.4 Immunohistochemistry  
 
For detailed information on the different protocols used, see each individual project in this 
thesis. For a brief summary may be mentioned that in the three rat projects we stained for 
MIB 5 (Ki67) and BrdU both of which are nucleus stainings for cell proliferation analysis. The 
human counterpart to MIB5, MIB1 was stained for in the fourth project. In paper II stainings 
for GSTπ and TrxR1 was performed and in the fourth paper stainings for Trx1, Trx2, Grx1, Grx2, 
Grx3 and Grx5 was done. 
BrdU and MIB5 indices were calculated in a light microscope (Microscope Nikon Eclipse 
E1000M) as the ratio of the total number of nuclei seen in one field to the number of positive 
stained nuclei. For the mitotic index the total number of nuclei was divided with the number 
of mitotic figures seen. The method was modified slightly between the different projects; in 
paper I and II, tissue sections were evaluated in 200X magnification and at least 1000 cells 
were counted until a cumulative mean value was reached.  
In paper III the cumulative mean from 15 randomly counted fields of the tissue slides was 
calculated in a magnification of 400X, and in the fourth paper the labeling index of MIB1 was 
counted in randomly fields in a magnification of 200X until a cumulative mean value was 
reached.  
 
2.2.5 Imaging analysis of IHC 
 
For quantification analysis of the staining level of thioredoxin and glutaredoxins an imaging 
analysis was set up using the software photoshop and NIS-Elements. The pictures of the slides 
were photographed under the light microscopy with standardized settings, blue color 
elimination was done in photoshop and analysis of the saturation was done using NIS-
Elements Br. For detailed information see project IV. 
 
2.2.6 Nodule and tumour density  
 
The number as well as the volume fraction of liver tumours in the rat cancer model was 
quantified using morphometric densitometry on tissue slides stained with Gst Yp. The number 
of focus profiles in the slice was divided by the area. The nodular volume density was 
expressed as % of the cellular volume. The number of foci/mm2 and the volume density of 
nodules were calculated in a computerized morphometric analyzer (Minimop, Kontron, 
Munich, Germany).  
 
2.2.7 Preparation of liver tissue homogenate 
In order to make a 20% homogenate of rat liver tissue, frozen samples was transferred to pre-
weighed tubes containing 1 mM EDTA (pH 7,5) and 50 mM tris-HCl in a total volume of 3 mL 
and weighed. The samples were minced with a pair of scissors and homogenized in a Potter-
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Elvehjelm glass-teflon homogenizer connected to a pillar drill. With four gentle up and down 
strokes at a speed of 440 rev/min the liver went completely homogenized, the homogenate 
was transferred to centrifuge tubes and were subsequently spun in an ultra-centrifuge at 
105,000 x gAV for 90 minutes at 4°C. The samples were kept cold through the whole process. 
Protein determination on the supernatant was made according to Lowry et al [157].  
 
2.2.8 Specific activity of Trx1 
 
The specific activity of TrxR1 was measured in rat liver homogenate by an enzyme assay 
according to A. Holmgren and M. Björnstedt [158]. Briefly, A sample containing 100 µg of 
protein was incubated with 80 mM Hepes, (pH 7,5), 0,9 mg/mL NADPH, 6 mM EDTA, 2 mg/mL 
insulin and 10 µM Escherichia coli  thioredoxin at 37°C for 20 minutes in a final volume of 120 
µL. For termination of the enzymatic reaction 0,4 mg/mL dithiobis 2-nitrobenzoic acid (DNTB) 
and 6M guanidine hydrochloride in 0,2 M Tris-HCl (pH 8,0) was added to the solution. Within 
20 minutes the absorbance was measured at 412 nm and the value of a corresponding blank 
sample without added Trx was subtracted. A standard curve was prepared using purified 
thioredoxin reductase from rat liver (Sigma). 
 
2.2.9 Protein detection 
 
For quantification of IL6 in rat serum the ELISA kit “Quantine Rat IL-6 Immunoassay” (R&D 
systems, Minneapolis, USA) was used. 
Western blot technique was used to quantify the protein expression of STAT3, Smad4, ppERK, 
pJNK and pp38 in rat liver tissue. For details please see the respective method section in study 
I and III. 
 
2.2.10 Statistical analysis 
 
Statistica software 9.0 and 10.0 has been used for statistical analysis. For analysis of normal 
distribution the Shapiro-Wilks test was used. One way analysis of variance (ANOVA), 
student’s t-test or Mann-Whitney U test was used for comparison of mRNA expression, 
enzyme activity, body weights, relative liver weights, labeling indices of BrdU and MIB5 and 
mitotic indices between animal groups and for comparison of immunohistochemical 
saturation in HCC versus CRC. For anthropometric and laboratory data, t-test was used for 
continuous data and Chi2 test or Fischer’s exact test when appropriate, for categorical data. 
The statistical significance of the values of saturation in tumors and its corresponding 
surrounding non-tumorous tissue was determined with paired t-test and Wilcoxon matched 
t-test. For correlation tests linear regression was used.  P value <0.5 were considered 
statistically significant. Error bars represent ±SD. Figures were created using 
GraphPadPrism5 (GraphPad Software, Inc., La Jolla, CA, USA).  
 
2.2.11 Ethical approval 
The studies in this thesis were approved by the Stockholm South local Committee for Ethical 
Review of Animal Experiments and by Stockholm Regional Ethics Committee. 
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2.3 RESULTS 
2.3.1 Paper I 
Iron-regulatory genes during liver regeneration. 
 
Background 
Liver regeneration is characterized by an acute-phase reaction during the first 18-24 h after a 
partial hepatectomy. Others have shown that during this phase IL6 is released which in turn 
stimulates hepcidin gene expression. Hepcidin however, decreases iron availability since it 
decreases iron uptake from the gut and iron release from macrophages, and therefore 
hepcidin-induced iron deficiency may impair liver regeneration. 
 
Aim 
We asked if other hepcidin-regulatory pathways would down-regulate hepcidin expression 
during the later phases of liver regeneration after surgery 
 
Methods 
We used a rat model comparing partial hepatectomy with sham operation. Liver tissue was 
sampled at different time points after surgery. Gene expression of hepcidin-regulatory 
molecules were quantified with real-time PCR and correlated to proliferation index, IL6 levels 
in plasma and STAT3 protein levels in liver tissue. 
 
Results 
During the acute-phase response after PH high serum levels of IL6 was seen inducing STAT3 
protein expression and mRNA of hepcidin. The gene expressions of proteins involved in the 
iron-sensing pathway (HFE, HJV and TfR2) were instead decreased while the mRNA levels of 
proteins involved in iron uptake (TfR1 and DMT1) were increased and transcripts of proteins 
involved in cellular iron export were unchanged (FPN and ceruloplasmin). In the regenerative 
phase after PH namely >24h post PH, gene expression of HFE and HJV belonging to the iron-
sensing pathway were continuously suppressed and mRNA levels of hepcidin declined. 
 
Conclusion 
Hepcidin gene expression peaks during the acute-phase response, but a sustained down-
regulation of the iron-sensing pathway of hepcidin regulation gradually reduces hepcidin gene 
expression until regeneration is complete, thereby promoting iron mobilization to the 
regenerating liver. 
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2.3.2 Paper II 
The effect of sodium selenite on liver growth and thioredoxin reductase expression in 
regenerative and neoplastic liver cell proliferation.  
 
Background 
A previous study performed in our lab showed that administration of sodium selenite reduced 
the volume fraction of preneoplastic nodules during the promotion as well as the volume 
fraction of neoplastic nodules during the progression 12 months after initiation. Selenium did 
not inhibit initiation in the DEN/2AAF + PH rat model [159].  
 
Aim 
The aim of this project was to investigate the effect of administration of sodium selenite on 
the neoplastic growth during progression in tumour development and compare that with the 
effect of selenite on the regenerative cell proliferation after PH. In addition we wanted to 
compare the expression of TrxR1 in regenerative liver to that in liver neoplasia to evaluate if 
TrxR1 could be considered as a constitutive tumour marker or only an unspecific marker for 
cell growth. 
 
Methods 
We performed two studies on rats, the first of which included chemical induction of cancer 
and treatment with sodium selenite, and the second included treatment with sodium selenite 
after PH.  
 
Results 
No effect on body weight or gain of liver mass could be seen after administration of sodium 
selenite followed by PH, even though a slight delay in the S-phase peak and mitosis could be 
seen. However, the tumour volume in the DEN/2AAF/PH model was significantly decreased in 
animals treated with sodium selenite during progression compared to animals not treated 
with selenium during progression. The expression of TrxR1 mRNA was not affected by 
administration of sodium selenite in the non-neoplastic regenerating liver cells and the activity 
of the enzyme was only transiently increased during the peak of cell proliferation. In the 
neoplastic liver lesions TrxR1 was constantly overexpressed in a way that did not correlate to 
the growth rate of the individual lesions or within the individual lesions. 
 
Conclusion 
Administration of 5 µg/µL sodium selenite did not compromise liver cell proliferation after PH 
in an extent that affected liver regeneration and gain of liver mass. In contrast to this effect 
the neoplastic liver nodules grew significantly slower in the selenite treated rats in comparison 
to the lesions in rats drinking tap water. The consistent over expression of TrxR1 in liver 
neoplasia contrasted to the transient increase in regenerating hepatocytes that was not even 
clearly visible by IHC. This made us suggest that the neoplastic overexpression of TrxR1 seen 
could only partly be explained by the tumour cell growth rate.  
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2.3.3 Paper III 
Sorafenib prolongs liver regeneration after hepatic resection in rats.  
 
Background 
Sorafenib is a multi-kinase inhibitor that targets the tyrosine kinase activity of growth factor 
receptors such as EGFR, PDGFR and VEGFR and also the threonine kinase activity of Raf in the 
Ras/Mek/ERK pathway. By binding to the ATP-binding pocket on these kinases sorafenib 
inhibits angiogenesis and cell proliferation. Sorafenib has been suggested as an adjuvant 
treatment in conjunction with hepatic resection for HCC, and therefore the effect of sorafenib 
on liver regeneration is of interest. 
 
Aim 
To investigate the effects of sorafenib treatment on liver enzymes, cell proliferation and liver 
weight gain during the entire length of liver regeneration after partial hepatectomy in rat. 
 
Methods 
Rats were administered sorafenib once daily for one week, and then underwent a 2/3 partial 
hepatectomy (PH). In the first study, sorafenib was given in three different doses (5, 10 and 15 
mg/kg/day) and animals sacrificed 0-24 hours after PH. In the second study, sorafenib 5 
mg/kg/day was given 0, 3 or 14 days after PH. The number of S-phase nuclei was calculated 
using immunohistochemistry, and pERK was analyzed with Western blot. 
 
Results 
Treatment with sorafenib increased the levels of serum ALT and serum AST in a dose-
dependent manner at baseline. The number of S-phase positive nuclei was increased at base-
line in animals treated with the highest dose (15 mg/kg).  Liver weights and levels of pERK 
were decreased at 24 hours post PH. 
 
At 48 hours after PH, the number of S-phase nuclei and mitotic indices were decreased in 
sorafenib-treated animals. At seven days after PH the number of S-phase positive nuclei was 
instead increased in animals treated with sorafenib 3 or 14 days after PH, as compared with 
controls. The relative liver weights were restored at day five in control rats, day seven in 
animals receiving sorafenib before surgery, day ten in rats where sorafenib treatment was 
ceased three days after surgery and at day 14 in rats were on continuous treatment with 
sorafenib. 
 
Conclusion 
In our rat model, sorafenib given in conjunction with a 2/3 PH decreased cell proliferation and 
prolonged the liver mass restoration in proportion to the length of sorafenib treatment. One 
week after PH, we found an adaptation to the inhibitory effects of sorafenib with increased 
cell proliferation in sorafenib-treated animals compared to that of the controls. 
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2.3.4 Paper IV 
Characterization of redox proteins in human hepatocellular carcinoma. 
 
Background 
Redox proteins like thioredoxins and glutaredoxins are ubiquitously expressed proteins 
involved in several biological processes. The expression of Trx and Grx is induced in many 
neoplasms and was found to correlate to the prognosis in colorectal and gallbladder 
carcinoma 
 
Aim 
The aim was to characterize the expression of Trx1 and 2 and Grx1, 2, 3 and 5 in human HCCs 
and investigate their possible association to clinical parameters and their value as prognostic 
markers for recurrence after resection for HCC. 
 
Methods 
Immunohistochemical stainings with antibodies specific for the six different redox proteins 
were made on liver sections from paraffin embedded resected liver tumours. The stainings 
were analyzed with a computer-based imaging method described in detailed in project IV. As 
internal control surrounding non-tumorous tissue was used and the ratio of saturation in 
tumour to the saturation in surrounding non-tumorous tissue was calculated. Gene expression 
was analyzed from five of the patients from fresh frozen liver tissue using quantitative real-
time PCR. Correlations of the IHC protein expression and clinical parameters were performed. 
As controls resected colorectal cancer (CRC) liver metastases were used. 
 
Results 
An up-regulation of Trx1, Trx2 and Grx5 was seen in HCCs compared to its respective 
surrounding non-tumorous tissue. The same was also observed in CRC metastases where also 
the saturation of Grx1 and Grx3 was significantly higher. In HCC, Trx1 correlated significantly to 
cell proliferation but not to tumour differentiation, micro-vascular invasion or tumour 
recurrence. A down regulation of Trx1 in tumours relative to the surrounding was seen in 
males compared to females and in smokers and in patients with high alcohol consumption. 
 
Conclusion 
Redox proteins investigated in the present study are more up-regulated in the surrounding 
livers of patients with HCC as compared with CRC liver metastases except for Grx2. The 
expressions in the tumours are also weaker in HCC compared to CRC. Our results suggest that 
the expression of Trx and Grx proteins reflects the grade of oxidative stress in chronic liver 
disease and mirrors the environmental state in the liver tissue that surrounds HCC. Our data 
indicates that redox proteins are ubiquitously expressed in livers exposed to oxidative stress 
and various malignancies and can therefore not be used as diagnostic markers for HCC. Even 
though a correlation between cell proliferation and the expression of Trx1 in tumours was 
found, patients with or without tumour recurrence were not significantly different in redox 
protein expressions, indicating that redox proteins lacks a prognostic significance in HCC. 
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3 DISCUSSION 
 
The underlying mechanisms of liver regeneration have been thoroughly studied the last 
decades and a complex and fine-tuned orchestration have emerged involving several signaling 
pathways. The significance of understanding these features is evident since a majority of liver 
cancers are induced in a highly proliferative environment. With a deeper insight to the exact 
mechanisms of tumour development, better tools for early diagnosis, prognosis, prediction 
and development of new treatments could be accomplished.  
The most studied phase of liver regeneration so far is the initiation, but new findings including 
the termination are arising. 
Given that the same signaling machinery lies behind normal regeneration and the 
regeneration that occurs during chronic liver repair eventually leading to malignancies, the 2/3 
PH rat-model permits the study of these pathways and may shed light on future targets for 
treatment of cancer or prevention of cancer development. 
This thesis comprises of four papers where the three first is conducted on the 2/3 partial 
hepatectomy rat model. We studied the expression of iron regulatory genes, the effect on 
regeneration after administration of sodium selenite and how the multi kinase inhibitor 
sorafenib influences the liver regeneration. In the second paper we also investigated the 
usefulness of TrxR1 as a neoplastic marker and selenium as a preventative agent in 
carcinogenesis. In the fourth paper we examined the role of redox proteins in human 
hepatocellular carcinoma and investigated the use of redox proteins as diagnostic or 
prognostic markers. 
In the study of the expression of iron-regulatory genes we used the 2/3 PH-model and 
sacrificed animals at different time points during the whole phase of liver regeneration. The 
aim was to elucidate the regulation not only during the acute-phase but also during the 
regenerative phase to see if the IL6 -induced acute-phase induction of hepcidin expression 
would persist or decline after the ending of the acute-phase reaction to facilitate iron 
mobilization to the growing cells. In earlier studies the expression of acute-phase proteins 
declined 18 hours after PH [160] but no studies have been performed to investigate the 
expression of the major key for iron homeostasis, hepcidin, during the later phases of liver 
regeneration. 
Our results showed a significant elevation of hepcidin expression starting at 2 hours post PH 
and peaked at 8 hours and declined after 16 hours. The control animals also had a peak at 8 
hours after the sham operation – although not as pronounced- and which is most likely an 
acute reaction to the opening of the abdomen. Elevated serum levels of IL6 however, could 
only be detected in the PH animals. The role of IL6 during the acute phase of liver regeneration 
is a well-established feature. After partial hepatectomy or other liver injuries this cytokine is 
released by Kupffer cells, and by binding to the hepatocytes starts the positive signal cascade 
JAK/STAT pathway that induce gene activation to promote proliferation.  We found increased 
levels of STAT3 in the PH animals but not in the SO ones. Our findings confirm previous work 
demonstrating an IL6 induced hepcidin gene expression during the acute-phase response after 
liver surgery [161]. Following the completion of the acute-phase response, which is 2-14 days 
after the hepatectomy, we saw a significant reduction of hepcidin mRNA levels as compared 
with levels found after sham operation. 
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At 48 hours post PH a reduction of the expression of hepcidin was seen compared to sham 
operated animals and at 72h and 1 w, this decrease was significant in the PH rats. At two and 
three weeks after the surgery the levels were the same in PH and SO animals. As in other 
studies, the expression of HJV was decreased during the acute phase. Expression of the three 
hepcidin-regulatory molecules TfR2, HFE and HJV was down-regulated during the whole 
process of regeneration suppressing hepcidin gene expression and thereby facilitating iron 
uptake, even if the transient induction of IL6 overrules this decrease in the acute phase. 
The expression of Transferrin receptor 1 was simultaneously over-expressed in the same 
pattern as hepcidin during the acute phase, indicating an increased iron uptake, although TfR1 
is also post-translationally stabilized by IRP which activity is activated during oxidative stress. 
Also the expression of the metallotransporter DMT1-IRE was over-expressed in comparison to 
the SO-animals. 
In a recent study conducted on mice, two important growth factors for regeneration, HGF and 
EGF, decreased the expression of hepcidin via PI3 kinase MEK/ERK pathway. This finding 
suggests a modulation of the BMP transcriptional regulators Smad1/5/8 and others and can 
serve as an explanation for high iron load in patients with chronic liver inflammation caused by 
hepatitis C virus or alcohol hepatitis [162]. 
In the first paper we thus concluded that a down-regulation of the iron-sensing pathway 
during the later phases of liver regeneration, when the effects of the acute-phase reaction had 
disappeared, leads to reduced hepcidin expression and enhanced iron mobilization to the 
growing liver. 
In the second paper we turned our interest to the effects of another trace element, namely 
selenium, on liver regeneration and neoplastic cell proliferation. We focused on the selenium-
containing enzyme thioredoxin-reductase1 (TrxR1) as a marker for neoplasia and/or 
proliferation, as well as the putative anti-tumoral effects of sodium selenite. 
We could see that the TrxR1 was overexpressed in the initiated cells and through all the steps 
of the carcinogenesis until liver cancers were formed. This expression persisted during the 
progression phase only in tumors and not in the remodeling nodules which remained in the 
progression phase. TrxR1 was thus over-expressed only in tumors with a neoplastic growth 
advantage and the remodeling liver nodules positive for the classical liver nodule marker GST-
π but negative for the S-phase marker BrdU, were also negative for TrxR1 during the late 
progression. The following observations from our immunohistochemical studies made us draw 
the conclusion that TrxR1 indeed is a constituent of the neoplastic phenotype and not only a 
proliferative marker:  (1) the TrxR1 immunohistochemical signal in the nodules was strong and 
homogenous within the lesions, and (2) the intensity of the signal was not correlated to the 
rate of cell proliferation measured as BrdU-index, or to the distribution of growing cells in the 
nodules. 
The increase in enzymatic activity of TrxR1 seen during the regenerative growth could not be 
detected by IHC, with one exception at 24 hours post PH where a weak signal in the periportal 
zone 1 could be detected in two rats of four in the group that was not treated with selenite. 
This induction of TrxR1 enzyme activity during regenerative cell proliferation was transient and 
noted only from 16 hours to 72 hours post PH.  These data indicate that TrxR1 indeed is a 
constituent of the neoplastic phenotype and a marker for neoplasia, although the expression 
of Trx1 can partially be explained by increased proliferation. As a component of the resistant 
phenotype which is induced during clonal adaptation and dysplasia, the expression of TrxR1 
could be regarded as a response to the toxicity of the carcinogenetic protocol used in this 
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model and thus be a part of the cell defense against free radicals and toxicity. The role of this 
selenoenzyme in cancer has been illustrated in an experiment on lung cancer cells where 
removal of TrxR1 by using siRNA-mediated knockdown, reverted the neoplastic phenotype 
and inhibited malignant characteristics. Moreover, a TrxR1 deficient cell line lost growth self-
sufficiency in both S-phase progression and expression of DNA polymerase [163]. In contrast to 
these data, transgenic mice with a deficient TrxR1 phenotype was not affected in normal liver 
development or during regeneration, indicating a TrxR1-independent route to supply RNR with 
electrons to provide for a complete DNA replication and normal proliferative growth [164].   
TrxR1 deficient cells have further been shown to up regulate glutathione and to increase the 
activity of glutaredoxins thus maintaining a redox steady state [165]. 
In the synchronized and sequential model of carcinogenesis used in this thesis we have shown 
that TrxR1 was over-expressed in the preneoplastic expanding clones as well as in growing 
neoplastic lesions during progression. Thus, the use of TrxR1 as an immunohistochemical 
marker for liver preneoplasia and/or neoplasia could be suggested. One drawback regarding 
the use of tissue markers are that liver biopsies are needed, a procedure that is not without 
risks for the patient, and also a costly method. We tried to measure the levels of TrxR1 in rat 
serum with a sensitive ELISA method but without success. A plasma or serum marker that is 
specific and sensitive for preneoplasia would be of great clinical value.  
We also administered sodium selenite to rats during liver regeneration and 
hepatocarcinogenesis. We found that this selenium compound reduced the nodule density 
during the progression phase of hepatocarcinogenesis but sodium selenite in the dose of 5 
µg/mL did not impair the normal liver regeneration. 
When we treated rats with 5 µg/mL a reduction of the expression of TrxR1 mRNA was 
observed in advanced liver cell carcinomas (data not published). This may indicate a different 
response to selenite in neoplastic cells to that of normal cells since a transiently increase in the 
mRNA expression was seen in normal regenerating hepatocytes. 
In a study done in our lab, long term administration of sodium selenite did neither cause toxic 
effects nor accumulation of selenium in liver tissue or serum, although the levels of selenium 
was initially increased in a dose dependent way [166].  
There are several reports about the tumour preventive effects of selenium but in a recent 
review these effects are questioned [167]. Based on over hundred studies of the selenium 
effect on different cancer types the authors of this review concluded that regular intake of 
selenium supplements for cancer prevention cannot be recommended to either the selenium-
replete or deficient populations, and they also suggested new and better studies in order to 
evaluate selenium as a preventive agent in cancer [167]. Thus, the anti-neoplastic effects of 
selenium compounds seen in the rat model of hepatocarcinogenesis used in the present study 
needs to be confirmed in clinical studies on humans. It is also important to consider that some 
organic selenium compounds, like selenomethionine seems to differ from inorganic, like 
sodium selenite, or other organic compounds like selenomethyselenocystein. 
So far, the only compound for systemic use which increases survival in patients with non-
resectable HCC is sorafenib. Sorafenib was registered in 2007 after the results of the SHARP 
trial demonstrated a survival benefit compared with placebo on advanced HCC [43]. Sorafenib 
is a multikinase inhibitor, inhibiting the tyrosine kinases of vascular endothelial growth factor 
receptor (VEGF-R), and also on kinases downstream this receptor such as threonine kinase 
activity of Raf in the Ras/Mek/ERK pathway, leading to decreased levels of phosphorylated ERK 
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and inhibition of cell division. Target cells are both hepatocytes and endothelial cells, making 
sorafenib a combined anti-angiogenic and anti-proliferative compound. 
The discovery of sorafenib was a big progress in the treatment of advanced liver cancer. 
However, sorafenib has side effects which must be taken into considerations when evaluating 
patients´ quality of life. Since sorafenib has been suggested as an adjuvant treatment after 
liver resection for HCC, the effects of sorafenib on liver regeneration is of interest. We 
therefore performed a study on the effects of sorafenib on liver regeneration using the same 
rat model as in paper I and II, namely the 2/3 PH rat model. 
In our first and short-term study we evaluated three doses of sorafenib, 5 mg, 10 mg and 15 
mg/kg bw, that was administered daily for one week before PH and then animals were 
sacrificed in groups of four at 16, 20 and 24 hours after PH. An additional group was sacrificed 
without any PH (0h). 
We could see a mild but non-significant effect on cell proliferation measured as MIB5 positive 
nuclei, while the relative liver weights were decreased in all doses at 24 hours. The levels of 
both ALT and AST were increased in a dose dependent manner at base-line (0h) and the 
highest dose gave an elevation of MIB5 positive nuclei indicating a toxic effect of the 
treatment with sorafenib inducing compensatory liver cell proliferation. 
In the long-term study in paper II we choose the 5 mg dose that was less toxic but still had an 
effect on liver growth after surgery.  Previous studies report the use of doses ranging from 5-
10 mg/kg [168]. 
In other similar studies conducted in mice conflicting results upon liver regeneration were 
shown. Hora et al showed inhibition of regeneration when sorafenib was administered after 
surgery but not if it was given before surgery. These results are in line with our data except for 
one important difference [169].  They could not detect any inhibiting effect on liver cell 
proliferation when sorafenib was stopped 24 hours before surgery while we saw a 
prolongation of the liver regeneration also in the “sorafenib pre-PH-group” in which treatment 
with sorafenib was stopped before PH. 
However, the last dose given in present study was two hours before PH. The half –life of 
sorafenib is 25-48 hours and the diverging results between their results and ours may be 
explained by the sorafenib dose given closer to the surgical event. The study by Hora et al. 
lasted until five days after surgery while we studied the whole regenerative process until 14 
days after surgery. Another murine study by Kurniali et al. could not detect any inhibitory 
effects of liver regeneration at the time points they measured which was 48 hours, 4 days and 
15 days after surgery [170].  However, in the study by Hora et al. the most marked effect on 
inhibition was seen at 72 hours post-surgery, and in the present study the most prominent 
inhibition was seen at 48 hours for BrdU positive nuclei and at 48 hours and 72 hours for 
inhibition of mitotic figures. Interestingly, at 7 days and 10 days we saw a compensatory 
increase in proliferation in the treated animals. 
One may speculate that the time points chosen in the Kurniali study failed to capture the 
inhibitory effect reported in ours and Hora´s study and also that a compensatory increase in 
cell proliferation that occurred in later time points may have masked a transient inhibitory 
effect of sorafenib.  
In a recent publication where rats received sorafenib for 14 days before PH in a dose of 15 
mg/kg body weight and sacrificed at day 2, 4 and 8 post hepatectomy, they showed results in 
line with our study [171]. The increase in proliferation in the treated animals seen in our study 
at day 7 was not seen at day 8 in their study. One explanation for these discrepancies can be 
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the dose, their dose being 3 times that of ours. Also, the period of increased proliferation 
might be missed because they sacrificed their animals at three time points only.  
In our study we can conclude that sorafenib prolonged the liver regeneration in proportion to 
the length of treatment. Interestingly, we saw that the liver cells adapted to the mitoinhibitory 
effect of sorafenib one week after surgery, and eventually reached a complete regeneration, 
but this was delayed until two weeks after surgery, which was significantly longer than the 
placebo animals, which completed their liver regeneration in 5 days. These findings indicate 
that sorafenib, if used in conjunction with surgery, prolongs regeneration but does not impair 
it completely. 
Studies have shown that cell lines adapted to the treatment of sorafenib and developed 
resistance upon long term treatment [172]. Hypothetically, treatment with sorafenib could 
select for the most aggressive growing tumour cells which in time may develop resistance. No 
studies so far on long term treatment have been reported, but this hypothesis has to be taken 
into consideration when giving sorafenib as a long-term prophylactic treatment in conjunction 
with resection or transplantation for HCC.   
Indeed, sorafenib has been tested as an adjuvant treatment preventing HCC recurrence after 
transplantation. The outcome was disappointing in one study [173], but other studies 
demonstrated better results [174, 175] with a delay of recurrence and metastases after liver 
transplantation [175]. In the post-transplantation setting, sorafenib is a safe and efficient 
therapy for recurrent HCC [176]. So far neither our data or data from others support a 
differentiated effect on surrounding and tumour tissue, respectively, that in theory could work 
as a selective force increasing the risk of relapse of sorafenib resistant HCC in long term 
treated patients. 
In the fourth paper we examined the difference in expression of the redox proteins Trx and 
Grx in hepatocellular carcinomas versus their surrounding tissue, and also correlated the 
expression to clinical parameters and elucidated if the expression of redox proteins could be 
used as diagnostic or prognostic markers for HCC. As internal controls we used the adjacent 
surrounding non-tumorous tissue and the relation of the expression in terms of color 
saturation after immunohistochemical staining was determined as the ratio of saturation in 
tumour to the saturation in the surrounding. The same was also done in CRC liver metastases 
patients and we compared the results with those of the HCCs. We found that the surrounding 
tissue in the resected HCC livers up-regulated redox proteins, even though the expression was 
higher in the tumours than in the surroundings. 
In HCC we found a significant higher ratio of the immunohistochemical saturation of Trx1, Trx2 
and Grx5 compared to respective surrounding non-tumorous tissue. In CRC liver metastases an 
even stronger up-regulation was seen in the tumours compared to the surrounding, which was 
seen for all redox proteins except for Grx2. The ratios of saturation of Trx1 and Grx3 in the 
tumours were significantly higher in CRCs compared to HCCs. This indicates a more prominent 
up-regulation of redox-proteins in CRCs than in HCC. This raised the question whether the 
difference seen was due to a stronger expression in the CRC tumours compared to HCCs, or 
stronger expression in HCC surrounding compared to CRC surrounding, or maybe both? 
To answer this question we compared the saturation of the immunohistochemical staining of 
Trx1 in all surroundings under the exact settings in the camera and microscope when shooting 
the photos and in the following processes in the computer when analyzing the saturation. We 
found that the saturations of Trx1 were significantly higher in HCC surroundings compared to 
the CRC surroundings. One explanation for these findings may be that since the HCCs resides 
44 
 
mostly in a liver with an underlying chronic liver disease with fibrosis and cirrhosis, there is an 
increases oxidative stress leading to an up-regulation of anti-oxidative defense systems like the 
thioredoxin and glutaredoxin systems. We draw the conclusion that redox proteins do not 
have a value as diagnostic markers for HCC since they are not specific for that tumour and also 
due to the up regulation seen in the surrounding tissue in chronic liver disease. 
To evaluate possible correlations between the expression of the redox proteins in HCCs and 
life-style factors such as smoking and alcohol consumption, we did correlation analysis and 
found decreased saturation ratios of Trx1 in the tumours relative to surrounding in smokers 
and in patients who drank more than 30 grams of alcohol per day. We found that after 
performing separate analysis of the saturation in tumours and surroundings, this difference 
was due to a significantly increased Trx1 expression in the surrounding livers from smokers 
and drinkers. 
The saturation of Trx1 in the tumours however did not differ compared with the non-smokers 
and those with low or moderate alcohol consumption. Accordingly, we concluded that 
drinking and smoking leads to an over-expression of Trx1 in the surrounding non-tumorous 
tissue while it does not affect the Trx1 level in the tumours themselves. A murine study 
demonstrated that Trx1 attenuated systemic inflammatory response in Trx1 overexpressing 
mice [177], indicating an important role of this protein in response to toxic induced oxidative 
stress.  
We also found a correlation between the metabolic syndrome and an up regulation of Grx2 in 
the HCCs, an indication of a different modulation of the redox defense system in this condition 
as compared to over-consumption of alcohol. Others have reported increased levels of 
thioredoxin in serum in patients with non-alcoholic steatohepatitis (NASH), which is a 
condition associated with the metabolic syndrome, indicating increased oxidative stress in this 
condition [20]. In a Chinese study of HBV associated HCC, metabolic changes was reported 
with up regulated antioxidant systems in patients with high levels of free fatty acids (FFA) 
[178]. 
We could not find any correlation between tumour differentiation and the expression levels of 
the redox proteins in HCC, however a significant inverse correlation between the total tumour 
diameter and the saturation levels of Trx2 was found, demonstrating a higher expression in 
patients with smaller HCCs.  There was also a non-significant trend towards increased Trx1 
protein expression in HCC tumours with micro-vascular invasion. 
Studies on redox proteins as prognostic markers have demonstrated that Trx1 expression in 
the invasive front was associated with a poor prognosis [124], and also in colorectal cancer 
liver metastases the expression of Trx1 was associated with bad prognosis [125]. All the CRCs 
were positive in our study which can be explained by the relatively low number of patients 
included.  
Tumour recurrence in the HCC patients of our study was 36% after a mean observation time of 
213 days, and we could not detect any differences in expression levels in this group compared 
to patients without recurrence. Possibly a longer observation time is needed to evaluate 
whether or not Trx and/or Grx protein expression differs between those with or without 
recurrence. Thus, from present data we cannot conclude that the expression of redox proteins 
can be of use as a prognostic marker in HCC. 
No correlation analysis between survival and redox proteins could be done because the 
observation time was too short with only 6 deceased patients. 
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We did correlation analysis of the IHC protein expression and mRNA expression and found a 
significant correlation in Trx1 but not Grx1. However, we had only fresh frozen material from 
five patients, but due the low number of samples and to sampling variability, these results 
must to be taken with caution.  
The cell proliferation varied both within and between tumours, but a correlation was found 
between high IHC ratios of Trx1 saturation in the tumours and the mean labeling index of the 
proliferation marker MIB5. We could also see a regional co expression of high proliferation and 
the expression of Trx1. The correlation between cell proliferation and Trx1 has been described 
earlier [179]. 
In conclusion, the present study demonstrates that redox proteins are up-regulated in the 
surrounding livers of patients with HCC as compared to those with CRC liver metastases, while 
the expression in the tumour itself is weaker in HCCs compared to CRC metastases. These data 
indicate that redox proteins are ubiquitously expressed in livers exposed to oxidative stress 
and various malignancies, and therefore cannot be used as diagnostic markers for HCC. Cell 
proliferation in HCCs correlated to the tumour expression of Trx1, but patients with tumour 
recurrence had similar redox expressions as those without, indicating that redox expressions 
lack a prognostic significance in HCC. 
 
 
3.1 GENERAL CONCLUSIONS 
 
 The iron-sensing pathway of hepcidin regulation is down-regulated during liver 
regeneration, which reduces hepcidin gene expression and promotes iron mobilization 
to the regenerating liver. 
 
 Treatment with sodium selenite reduces tumour volume in a rat model of 
hepatocarcinogenesis, but does not significantly compromise proliferation of normal 
hepatocytes during regeneration. 
 
 Overexpression of TrxR1 is a constituent of the neoplastic phenotype. 
 
 In a rat model of partial hepatectomy, sorafenib decreases cell proliferation and 
prolongs liver regeneration in proportion to the length of treatment. There is a partial 
adaptation to the inhibitory effects of sorafenib one week after the surgical event. 
 
 Thioredoxins and glutaredoxins are ubiquitously expressed in livers exposed to oxidative 
stress and various malignancies and can therefore not be used as diagnostic markers for 
HCC. Smoking and high alcohol consumption increase Trx1 expression in tissue 
surrounding the HCCs, whereas expression of Trx1 in the HCCs correlates to cell 
proliferation. Redox protein expression in HCCs cannot predict tumour recurrence after 
liver resection. 
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3.2 FUTURE PERSPECTIVES  
 
It is well known that the cytokine IL6 is crucial for induction of liver regeneration after partial 
hepatectomy. In our study we found an IL6 induction followed by increased hepcidin gene 
expression after surgery. However, it is unknown if hepcidin itself is essential for liver 
regeneration. This could be investigated using by the gene-knocking out method siRNA in cell 
lines. 
 
Given the result in paper II where we concluded that TrxR1 was a constituent of the neoplastic 
phenotype, it would be of interest to evaluate the diagnostic and prognostic significance of 
this enzyme in human HCCs. Another interesting protein involved in coordination of regulation 
of genes involved in the response to oxidative stress is nuclear factor erythroid 2 related factor 
2 (Nrf2). This factor was reported to be persistent activated in liver cancer cell lines and in 
mice [180].  
 
We showed that selenium had inhibitory effects on tumours in our rat model of 
hepatocarcinogenesis without impairing the growth of normal hepatocytes. We also showed 
that sorafenib prolonged the regeneration after PH in rat. One could speculate that selenium 
and sorafenib in combination could have beneficial effects in the treatment of human 
hepatocarcinogenesis. Thus, It would be interesting to evaluate if a combination treatment 
with sorafenib and selenium would enhance the inhibitory effect on liver tumours in rats and if 
so, the dose of sorafenib could be lowered to decrease side effects and still be an efficient 
mitoinhibitor.  
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